



## Clinical trial results:

**A Phase 3, observer-blind, randomized, placebo-controlled study to evaluate the non-inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50-59 years of age, including adults at increased risk of respiratory syncytial virus lower respiratory tract disease, compared to older adults  $\geq 60$  years of age**

### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2022-001981-36   |
| Trial protocol           | DE ES NL PL      |
| Global end of trial date | 12 February 2024 |

### Results information

|                                |              |
|--------------------------------|--------------|
| Result version number          | v1           |
| This version publication date  | 26 June 2024 |
| First version publication date | 26 June 2024 |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 219238 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | GlaxoSmithKline   |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330                                  |
| Public contact               | GSK Response Center, GlaxoSmithKline, 44 8664357343, GSKClinicalSupportHD@gsk.com |
| Scientific contact           | GSK Response Center, GlaxoSmithKline, 44 8664357343, GSKClinicalSupportHD@gsk.com |

Notes:

### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                  |
|--|------------------|
| Analysis stage                                       | Interim          |
| Date of interim/final analysis                       | 13 March 2023    |
| Is this the analysis of the primary completion data? | Yes              |
| Primary completion date                              | 13 March 2023    |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 12 February 2024 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

- To demonstrate the non-inferiority (NI) of the humoral immune response in healthy participants 50-59 years of age (YOA) compared to OA ( $\geq 60$  YOA) for the RSV-A strain after RSVPreF3 OA investigational vaccine administration.
- To demonstrate the NI of the humoral immune response in healthy participants 50-59 YOA compared to OA for the RSV-B strain after RSVPreF3 OA investigational vaccine administration.
- To demonstrate the NI of the humoral immune response in participants 50-59 YOA at increased risk of RSV-LRTD compared to OA for the RSV-A strain after RSVPreF3 OA investigational vaccine administration.
- To demonstrate the NI of the humoral immune response in participants 50-59 YOA at increased risk of RSV-LRTD compared to OA for the RSV-B strain after RSVPreF3 OA investigational vaccine administration.

Protection of trial subjects:

Study participants were observed closely for at least 30 minutes after the administration of the study interventions. Appropriate medical treatment was readily available during the observation period in case of anaphylaxis or syncope.

Background therapy: -

Evidence for comparator: -

|   |                 |
|---|-----------------|
| Actual start date of recruitment                          | 28 October 2022 |
| Long term follow-up planned                               | No              |
| Independent data monitoring committee (IDMC) involvement? | No              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Argentina: 179     |
| Country: Number of subjects enrolled | Canada: 223        |
| Country: Number of subjects enrolled | Germany: 248       |
| Country: Number of subjects enrolled | Japan: 152         |
| Country: Number of subjects enrolled | Netherlands: 39    |
| Country: Number of subjects enrolled | Poland: 144        |
| Country: Number of subjects enrolled | Spain: 199         |
| Country: Number of subjects enrolled | United States: 360 |
| Worldwide total number of subjects   | 1544               |
| EEA total number of subjects         | 630                |

Notes:

| <b>Subjects enrolled per age group</b>    |      |
|---|------|
| In utero                                  | 0    |
| Preterm newborn - gestational age < 37 wk | 0    |
| Newborns (0-27 days)                      | 0    |
| Infants and toddlers (28 days-23 months)  | 0    |
| Children (2-11 years)                     | 0    |
| Adolescents (12-17 years)                 | 0    |
| Adults (18-64 years)                      | 1273 |
| From 65 to 84 years                       | 264  |
| 85 years and over                         | 7    |

## Subject disposition

### Recruitment

Recruitment details:

Out of 1544 participants enrolled in this study, only 1534 received at least one study intervention, from which 1 participant in OA-RSV group received placebo instead of RSVPreF3 OA vaccine and was excluded from the group. The Exposed set included only 1533 participants.

### Pre-assignment

Screening details:

The results for this study were reported until Day 31 for immunogenicity analysis and up to Month 6 for safety analyses, since this is a primary completion posting. Data for final analysis will be updated at the time of End of Study (Final posting).

### Period 1

|                              |   |
|------------------------------|---|
| Period 1 title               | Overall Study (overall period)                                |
| Is this the baseline period? | Yes   |
| Allocation method            | Randomised - controlled                                       |
| Blinding used                | Double blind  |
| Roles blinded                | Subject, Investigator, Monitor, Data analyst, Carer, Assessor |

### Arms

|                              |                     |
|------------------------------|---------------------|
| Are arms mutually exclusive? | Yes                 |
| <b>Arm title</b>             | Adults HA-RSV Group |

Arm description:

Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

|  |                                     |
|--|-------------------------------------|
| Arm type                               | Experimental                        |
| Investigational medicinal product name | RSVPreF3 OA vaccine                 |
| Investigational medicinal product code |                                     |
| Other name                             |                                     |
| Pharmaceutical forms                   | Powder for suspension for injection |
| Routes of administration               | Intramuscular use                   |

Dosage and administration details:

One 0.5mL dose administered at Day 1 in the deltoid of the non-dominant arm.

|                  |                         |
|------------------|-------------------------|
| <b>Arm title</b> | Adults HA-Placebo Group |
|------------------|-------------------------|

Arm description:

Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

|  |                        |
|--|------------------------|
| Arm type                               | Placebo                |
| Investigational medicinal product name | Sodium chloride (NaCl) |
| Investigational medicinal product code |                        |
| Other name                             |                        |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intramuscular use      |

Dosage and administration details:

One dose of approximately 0.7 mL of NaCl solution administered at Day 1 in the deltoid of the non-dominant arm.

|                  |                      |
|------------------|----------------------|
| <b>Arm title</b> | Adults AIR-RSV Group |
|------------------|----------------------|

Arm description:

Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

|  |                                     |
|--|-------------------------------------|
| Arm type                               | Experimental                        |
| Investigational medicinal product name | RSVPreF3 OA vaccine                 |
| Investigational medicinal product code |                                     |
| Other name                             |                                     |
| Pharmaceutical forms                   | Powder for suspension for injection |
| Routes of administration               | Intramuscular use                   |

Dosage and administration details:

One 0.5mL dose administered at Day 1 in the deltoid of the non-dominant arm.

|                  |                          |
|------------------|--------------------------|
| <b>Arm title</b> | Adults AIR-Placebo Group |
|------------------|--------------------------|

Arm description:

Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

|  |                        |
|--|------------------------|
| Arm type                               | Placebo                |
| Investigational medicinal product name | Sodium chloride (NaCl) |
| Investigational medicinal product code |                        |
| Other name                             |                        |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intramuscular use      |

Dosage and administration details:

One dose of approximately 0.7 mL of NaCl solution administered at Day 1 in the deltoid of the non-dominant arm.

|                  |              |
|------------------|--------------|
| <b>Arm title</b> | OA-RSV Group |
|------------------|--------------|

Arm description:

Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

|  |                                     |
|--|-------------------------------------|
| Arm type                               | Experimental                        |
| Investigational medicinal product name | RSVPreF3 OA vaccine                 |
| Investigational medicinal product code |                                     |
| Other name                             |                                     |
| Pharmaceutical forms                   | Powder for suspension for injection |
| Routes of administration               | Intramuscular use                   |

Dosage and administration details:

One 0.5mL dose administered at Day 1 in the deltoid of the non-dominant arm.

| <b>Number of subjects in period 1<sup>[1]</sup></b> | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group |
|---|---------------------|-------------------------|----------------------|
| Started   | 383                 | 192                     | 386                  |
| Completed   | 380                 | 191                     | 384                  |
| Not completed                                       | 3                   | 1                       | 2                    |
| Lost to follow-up                                   | 3                   | -                       | 2                    |
| Consent withdrawal, not due to a (S)AE              | -                   | 1                       | -                    |

| <b>Number of subjects in period 1<sup>[1]</sup></b> | Adults AIR-Placebo Group | OA-RSV Group |
|---|--------------------------|--------------|
| Started   | 191                      | 381          |
| Completed   | 190                      | 381          |
| Not completed                                       | 1                        | 0            |

|  |   |   |
|--|---|---|
| Lost to follow-up                      | - | - |
| Consent withdrawal, not due to a (S)AE | 1 | - |

---

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The baseline period is reporting the number of participants included in the Exposed set, the worldwide number of participants is reporting the number of participants included in the Enrolled set.

## Baseline characteristics

### Reporting groups

|  |                          |
|--|--------------------------|
| Reporting group title  | Adults HA-RSV Group      |
| Reporting group description:<br>Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end. |                          |
| Reporting group title  | Adults HA-Placebo Group  |
| Reporting group description:<br>Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.   |                          |
| Reporting group title  | Adults AIR-RSV Group     |
| Reporting group description:<br>Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.   |                          |
| Reporting group title  | Adults AIR-Placebo Group |
| Reporting group description:<br>Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.   |                          |
| Reporting group title  | OA-RSV Group             |
| Reporting group description:<br>Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.  |                          |

| Reporting group values                        | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group |
|---|---------------------|-------------------------|----------------------|
| Number of subjects                            | 383                 | 192                     | 386                  |
| Age categorical<br>Units: Subjects            |                     |                         |                      |
| Adults (50-59 years)                          | 383                 | 192                     | 386                  |
| Adults (60-69 years)                          | 0                   | 0                       | 0                    |
| Adults (70-79 years)                          | 0                   | 0                       | 0                    |
| 80 years and above                            | 0                   | 0                       | 0                    |
| Age continuous<br>Units: years                |                     |                         |                      |
| median  | 54.8                | 54.7                    | 55.3                 |
| standard deviation                            | ± 2.8               | ± 2.8                   | ± 2.8                |
| Sex: Female, Male<br>Units: Participants      |                     |                         |                      |
| MALE  | 162                 | 73                      | 200                  |
| FEMALE  | 221                 | 119                     | 186                  |
| Race/Ethnicity, Customized<br>Units: Subjects |                     |                         |                      |
| American Indian or Alaska Native              | 1                   | 0                       | 4                    |
| Asian   | 41                  | 22                      | 42                   |
| Black or African American                     | 14                  | 8                       | 15                   |
| Native Hawaiian or other Pacific Islander     | 0                   | 0                       | 0                    |
| White   | 320                 | 158                     | 324                  |
| Multiple                                      | 4                   | 3                       | 1                    |

|         |   |   |   |
|---------|---|---|---|
| Unknown | 3 | 1 | 0 |
|---------|---|---|---|

|  |               |               |               |
|--|---------------|---------------|---------------|
| Age, Continuous<br>Units: YEARS<br>arithmetic mean<br>standard deviation | 54.8<br>± 2.8 | 54.7<br>± 2.8 | 55.3<br>± 2.8 |
|--|---------------|---------------|---------------|

| <b>Reporting group values</b>  | Adults AIR-Placebo Group | OA-RSV Group  | Total |
|--|--------------------------|---------------|-------|
| Number of subjects   | 191                      | 381           | 1533  |
| Age categorical<br>Units: Subjects                                       |                          |               |       |
| Adults (50-59 years)   | 191                      | 0             | 1152  |
| Adults (60-69 years)   | 0                        | 202           | 202   |
| Adults (70-79 years)   | 0                        | 130           | 130   |
| 80 years and above   | 0                        | 49            | 49    |
| Age continuous<br>Units: years<br>median<br>standard deviation           | 55.6<br>± 2.8            | 69.5<br>± 6.9 | -     |
| Sex: Female, Male<br>Units: Participants                                 |                          |               |       |
| MALE   | 106                      | 193           | 734   |
| FEMALE   | 85                       | 188           | 799   |
| Race/Ethnicity, Customized<br>Units: Subjects                            |                          |               |       |
| American Indian or Alaska Native   | 3                        | 1             | 9     |
| Asian  | 23                       | 43            | 171   |
| Black or African American  | 3                        | 11            | 51    |
| Native Hawaiian or other Pacific Islander                                | 2                        | 1             | 3     |
| White  | 158                      | 324           | 1284  |
| Multiple   | 1                        | 0             | 9     |
| Unknown  | 1                        | 1             | 6     |
| Age, Continuous<br>Units: YEARS<br>arithmetic mean<br>standard deviation | 55.6<br>± 2.8            | 69.5<br>± 6.9 | -     |



## End points

### End points reporting groups

|  |                          |
|--|--------------------------|
| Reporting group title  | Adults HA-RSV Group      |
| Reporting group description:<br>Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-Lower respiratory tract disease (RSV-LRTD), aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end. |                          |
| Reporting group title  | Adults HA-Placebo Group  |
| Reporting group description:<br>Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.   |                          |
| Reporting group title  | Adults AIR-RSV Group     |
| Reporting group description:<br>Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.   |                          |
| Reporting group title  | Adults AIR-Placebo Group |
| Reporting group description:<br>Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.   |                          |
| Reporting group title  | OA-RSV Group             |
| Reporting group description:<br>Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.  |                          |

### Primary: RSV-A neutralization titers expressed as group geometric mean titer (GMT) in healthy participants compared to OA-RSV Group

|  |   |
|--|---|
| End point title  | RSV-A neutralization titers expressed as group geometric mean titer (GMT) in healthy participants compared to OA-RSV Group <sup>[1]</sup> |
| End point description:<br>Serological assays for the determination of antibodies against RSV-A were performed by neutralization assay. The corresponding antibody titers were expressed in Estimated Dilution 60 (ED60) and were measured on blood samples collected from vaccinated maternal subjects. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA_RSV and OA_RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan. Analysis was performed on the per protocol set (PPS) for humoral analysis which included all eligible participants who received the study intervention as per protocol, had RSV-A immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. |   |
| End point type   | Primary   |
| End point timeframe:<br>At 1 month after the RSVPreF3 OA vaccine administration (Day 31)   |   |

#### Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults HA-RSV Group compared to OA-RSV Group.

| End point values                         | Adults HA-RSV Group       | OA-RSV Group              |  |  |
|--|---------------------------|---------------------------|--|--|
| Subject group type                       | Reporting group           | Reporting group           |  |  |
| Number of subjects analysed              | 326                       | 342                       |  |  |
| Units: Titer                             |                           |                           |  |  |
| geometric mean (confidence interval 95%) | 7893.5 (7167.5 to 8692.9) | 7492.6 (6819.1 to 8232.7) |  |  |

## Statistical analyses

| Statistical analysis title  | RSV-A ratio in OA-RSV over Adults-HA-RSV groups |
|---|---|
| Statistical analysis description:   |   |
| To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to healthy adults aged 50-59 years of age compared with older adults aged 60 years of age or above. |   |
| Comparison groups   | Adults HA-RSV Group v OA-RSV Group              |
| Number of subjects included in analysis   | 668   |
| Analysis specification  | Pre-specified                                   |
| Analysis type   |   |
| Parameter estimate  | GMT Ratio                                       |
| Point estimate  | 0.95  |
| Confidence interval   |   |
| level   | 95 %  |
| sides   | 2-sided   |
| lower limit   | 0.83  |
| upper limit   | 1.09  |

## Primary: RSV-A neutralization titers expressed as group seroresponse rate (SRR) difference in healthy participants compared to OA-RSV group

|                 |   |
|-----------------|---|
| End point title | RSV-A neutralization titers expressed as group seroresponse rate (SRR) difference in healthy participants compared to OA-RSV group <sup>[2]</sup> |
|-----------------|---|

### End point description:

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to 4 ( $\geq 4$ ).

Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had SRR results for RSV-A at pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

### End point timeframe:

At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)

### Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The purpose of this endpoint was to present analysis only for Adults HA-RSV Group compared to OA-RSV Group.

|                                   |                     |                     |  |  |
|-----------------------------------|---------------------|---------------------|--|--|
| <b>End point values</b>           | Adults HA-RSV Group | OA-RSV Group        |  |  |
| Subject group type                | Reporting group     | Reporting group     |  |  |
| Number of subjects analysed       | 270                 | 275                 |  |  |
| Units: Percentage of participants |                     |                     |  |  |
| number (confidence interval 95%)  | 82.8 (78.3 to 86.8) | 80.4 (75.8 to 84.5) |  |  |

## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>   | SRR ratio in OA-RSV minus Adults-HA-RSV groups |
| Statistical analysis description:   |  |
| To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to healthy adults aged 50-59 years of age compared with older adults aged 60 years of age or above. |  |
| Comparison groups   | Adults HA-RSV Group v OA-RSV Group             |
| Number of subjects included in analysis   | 545  |
| Analysis specification  | Pre-specified                                  |
| Analysis type   |  |
| Parameter estimate  | Difference in percentage                       |
| Point estimate  | -2.41  |
| Confidence interval   |  |
| level   | 95 %   |
| sides   | 2-sided  |
| lower limit   | -8.3   |
| upper limit   | 3.5  |

## Primary: RSV-B neutralization titers expressed as group GMT in healthy participants compared to OA-RSV Group

|                 |  |
|-----------------|--|
| End point title | RSV-B neutralization titers expressed as group GMT in healthy participants compared to OA-RSV Group <sup>[3]</sup> |
|-----------------|--|

### End point description:

Serological assays for the determination of antibodies against RSV-B were performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult HA\_RSV and OA\_RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan. Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had RSV-B immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

### End point timeframe:

At 1 month after the RSVPreF3 OA vaccine administration (Day 31)

### Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults HA-RSV Group compared to OA-RSV Group.

| End point values                         | Adults HA-RSV Group       | OA-RSV Group              |  |  |
|--|---------------------------|---------------------------|--|--|
| Subject group type                       | Reporting group           | Reporting group           |  |  |
| Number of subjects analysed              | 326                       | 341                       |  |  |
| Units: Titer                             |                           |                           |  |  |
| geometric mean (confidence interval 95%) | 9009.5 (8226.6 to 9866.6) | 8058.2 (7373.1 to 8807.0) |  |  |

## Statistical analyses

| Statistical analysis title  | RSV-B ratio in OA-RSV over Adults-HA-RSV groups |
|---|---|
| Statistical analysis description:   |   |
| To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to healthy adults aged 50-59 years of age compared with older adults aged 60 years of age or above. |   |
| Comparison groups   | Adults HA-RSV Group v OA-RSV Group              |
| Number of subjects included in analysis   | 667   |
| Analysis specification  | Pre-specified                                   |
| Analysis type   |   |
| Parameter estimate  | GMT Ratio                                       |
| Point estimate  | 0.89  |
| Confidence interval   |   |
| level   | 95 %  |
| sides   | 2-sided   |
| lower limit   | 0.79  |
| upper limit   | 1.02  |

## Primary: RSV-B neutralization titers expressed as group SRR in healthy participants compared to OA-RSV Group

|                 |  |
|-----------------|--|
| End point title | RSV-B neutralization titers expressed as group SRR in healthy participants compared to OA-RSV Group <sup>[4]</sup> |
|-----------------|--|

### End point description:

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration)  $\geq 4$ . Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had SRR results for RSV-B at pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

### End point timeframe:

At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)

### Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults HA-RSV Group compared to OA-RSV Group.

| End point values                  | Adults HA-RSV Group | OA-RSV Group        |  |  |
|-----------------------------------|---------------------|---------------------|--|--|
| Subject group type                | Reporting group     | Reporting group     |  |  |
| Number of subjects analysed       | 255                 | 254                 |  |  |
| Units: Percentage of participants |                     |                     |  |  |
| number (confidence interval 95%)  | 78.2 (73.3 to 82.6) | 74.5 (69.5 to 79.0) |  |  |

## Statistical analyses

| Statistical analysis title  | SRR ratio in OA-RSV minus Adults-HA-RSV groups |
|---|--|
| Statistical analysis description:   |  |
| To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to healthy adults aged 50-59 years of age compared with older adults aged 60 years of age or above. |  |
| Comparison groups   | Adults HA-RSV Group v OA-RSV Group             |
| Number of subjects included in analysis   | 509  |
| Analysis specification  | Pre-specified                                  |
| Analysis type   |  |
| Parameter estimate  | Difference in percentage                       |
| Point estimate  | -3.73  |
| Confidence interval   |  |
| level   | 95 %   |
| sides   | 2-sided  |
| lower limit   | -10.17   |
| upper limit   | 2.74   |

## Primary: RSV-A neutralization titers expressed as group GMT titer in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group

|                 |   |
|-----------------|---|
| End point title | RSV-A neutralization titers expressed as group GMT titer in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group <sup>[5]</sup> |
|-----------------|---|

### End point description:

Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-A neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR\_RSV and OA\_RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan. Analysis was performed on the per protocol set (PPS) for humoral analysis which included all eligible participants who received the study intervention as per protocol, had RSV-A immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

### End point timeframe:

At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31)

### Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults-AIR-RSV Group compared to OA-RSV Group.

| End point values                         | Adults AIR-RSV Group      | OA-RSV Group              |  |  |
|--|---------------------------|---------------------------|--|--|
| Subject group type                       | Reporting group           | Reporting group           |  |  |
| Number of subjects analysed              | 343                       | 342                       |  |  |
| Units: Titer                             |                           |                           |  |  |
| geometric mean (confidence interval 95%) | 8922.7 (8118.2 to 9806.9) | 7440.1 (6768.4 to 8178.5) |  |  |

## Statistical analyses

| Statistical analysis title | RSV-A ratio in OA-RSV over Adults-AIR-RSV groups |
|----------------------------|--|
|----------------------------|--|

Statistical analysis description:

To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to adults at increased risk of RSV-LRTD aged 50-59 years of age compared with older adults aged 60 years of age or above.

|   |                                     |
|---|-------------------------------------|
| Comparison groups                       | Adults AIR-RSV Group v OA-RSV Group |
| Number of subjects included in analysis | 685                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           |                                     |
| Parameter estimate                      | GMT Ratio                           |
| Point estimate                          | 0.83                                |
| Confidence interval                     |                                     |
| level                                   | 95 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | 0.73                                |
| upper limit                             | 0.95                                |

## Primary: RSV-A neutralization titers expressed as group SRR in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group

|                 |   |
|-----------------|---|
| End point title | RSV-A neutralization titers expressed as group SRR in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group <sup>[6]</sup> |
|-----------------|---|

End point description:

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration)  $\geq 4$ . Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had SRR results for RSV-A at pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after the RSVPreF3 OA vaccine administration (Day 31) compared to baseline (Day 1)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The purpose of this endpoint was to present analysis only for Adults-AIR-RSV Group compared to OA-RSV Group.

| End point values                  | Adults AIR-RSV Group | OA-RSV Group        |  |  |
|-----------------------------------|----------------------|---------------------|--|--|
| Subject group type                | Reporting group      | Reporting group     |  |  |
| Number of subjects analysed       | 298                  | 275                 |  |  |
| Units: Percentage of participants |                      |                     |  |  |
| number (confidence interval 95%)  | 86.9 (82.8 to 90.3)  | 80.4 (75.8 to 84.5) |  |  |

## Statistical analyses

| Statistical analysis title | SRR ratio in OA-RSV minus Adults-AIR-RSV groups |
|----------------------------|---|
|----------------------------|---|

Statistical analysis description:

To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to adults at increased risk of RSV-LRTD aged 50-59 years of age compared with older adults aged 60 years of age or above.

|   |                                     |
|---|-------------------------------------|
| Comparison groups                       | Adults AIR-RSV Group v OA-RSV Group |
| Number of subjects included in analysis | 573                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           |                                     |
| Parameter estimate                      | Difference in percentage            |
| Point estimate                          | -6.47                               |
| Confidence interval                     |                                     |
| level                                   | 95 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -12.05                              |
| upper limit                             | -0.94                               |

## Primary: RSV-B neutralization titers expressed as group GMT in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group

|                 |   |
|-----------------|---|
| End point title | RSV-B neutralization titers expressed as group GMT in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group <sup>[7]</sup> |
|-----------------|---|

End point description:

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. The ANCOVA model used to calculate the adjusted GMTs for RSV-B neutralizing antibodies included the baseline value as covariate (i.e. GMTs are adjusted for the PRE timepoint values) and only included Adult AIR\_RSV and OA\_RSV groups in the model as fixed effect, as specified in Statistical Analysis Plan. Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had RSV-B immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At 1 month after the RSVPreF3 OA vaccine administration (Day 31)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults-AIR-RSV Group compared to OA-RSV Group.

| End point values                         | Adults AIR-RSV Group           | OA-RSV Group              |  |  |
|--|--------------------------------|---------------------------|--|--|
| Subject group type                       | Reporting group                | Reporting group           |  |  |
| Number of subjects analysed              | 343                            | 341                       |  |  |
| Units: Titer                             |                                |                           |  |  |
| geometric mean (confidence interval 95%) | 10054.7<br>(9225.4 to 10958.7) | 8062.8 (7395.9 to 8789.9) |  |  |

## Statistical analyses

| Statistical analysis title  | RSV-B ratio in OA-RSV over Adults AIR-RSV groups |
|---|--|
| Statistical analysis description:   |  |
| To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to adults at increased risk of RSV-LRTD aged 50-59 years of age compared with older adults aged 60 years of age or above. |  |
| Comparison groups   | Adults AIR-RSV Group v OA-RSV Group              |
| Number of subjects included in analysis   | 684  |
| Analysis specification  | Pre-specified                                    |
| Analysis type   |  |
| Parameter estimate  | GMT Ratio  |
| Point estimate  | 0.8  |
| Confidence interval   |  |
| level   | 95 %   |
| sides   | 2-sided  |
| lower limit   | 0.71   |
| upper limit   | 0.91   |

## Primary: RSV-B neutralization titers expressed as group SRR in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group

|                 |   |
|-----------------|---|
| End point title | RSV-B neutralization titers expressed as group SRR in participants at increased risk of RSV-LRTD (Adults-AIR-RSV group) compared to OA-RSV group <sup>[8]</sup> |
|-----------------|---|

### End point description:

The SRR is defined as the proportion of participants having a fold increase in neutralization titers (1 month post-study intervention administration over pre-study intervention administration)  $\geq 4$ . Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had SRR results for RSV-B at pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

### End point timeframe:

At 1 month after the RSVPreF3 OA investigational vaccine administration (Day 31) compared to baseline (Day 1)

### Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The purpose of this endpoint was to present analysis only for Adults-AIR-RSV Group compared to OA-RSV Group.



|                                   |                      |                     |  |  |
|-----------------------------------|----------------------|---------------------|--|--|
| <b>End point values</b>           | Adults AIR-RSV Group | OA-RSV Group        |  |  |
| Subject group type                | Reporting group      | Reporting group     |  |  |
| Number of subjects analysed       | 280                  | 254                 |  |  |
| Units: Percentage of participants |                      |                     |  |  |
| number (confidence interval 95%)  | 81.6 (77.1 to 85.6)  | 74.5 (69.5 to 79.0) |  |  |

## Statistical analyses

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | SRR ratio in OA-RSV minus Adults AIR-RSV groups |
|-----------------------------------|---|

Statistical analysis description:

To demonstrate the non-inferiority of the RSVPreF3 OA vaccine when administered to adults at increased risk of RSV-LRTD aged 50-59 years of age compared with older adults aged 60 years of age or above.

|   |                                     |
|---|-------------------------------------|
| Comparison groups                       | Adults AIR-RSV Group v OA-RSV Group |
| Number of subjects included in analysis | 534                                 |
| Analysis specification                  | Pre-specified                       |
| Analysis type                           |                                     |
| Parameter estimate                      | Difference in percentage            |
| Point estimate                          | -7.15                               |
| Confidence interval                     |                                     |
| level                                   | 95 %                                |
| sides                                   | 2-sided                             |
| lower limit                             | -13.34                              |
| upper limit                             | -0.94                               |

## Secondary: Percentage of participants reporting each solicited administration site event (pain, redness and swelling)

|                 |  |
|-----------------|--|
| End point title | Percentage of participants reporting each solicited administration site event (pain, redness and swelling) |
|-----------------|--|

End point description:

Assessed solicited administration site events were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Any erythema and swelling symptom = symptom reported with a surface diameter greater than 0 millimeters.

Analysis was based on the Exposed Set (ES), which included all participants who received the study intervention and had data for solicited administration site events analysis at the assessed timeframe.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)

| End point values                  | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-----------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed       | 377                 | 191                     | 379                  | 188                      |
| Units: Percentage of participants |                     |                         |                      |                          |
| number (confidence interval 95%)  |                     |                         |                      |                          |
| Erythema                          | 11.9 (8.8 to 15.6)  | 0.5 (0.0 to 2.9)        | 14.5 (11.1 to 18.5)  | 0.5 (0.0 to 2.9)         |
| Pain                              | 76.4 (71.8 to 80.6) | 10.5 (6.5 to 15.7)      | 75.2 (70.5 to 79.5)  | 13.8 (9.2 to 19.6)       |
| Swelling                          | 9.3 (6.6 to 12.7)   | 1.0 (0.1 to 3.7)        | 11.6 (8.6 to 15.3)   | 0.5 (0.0 to 2.9)         |

| End point values                  | OA-RSV Group        |  |  |  |
|-----------------------------------|---------------------|--|--|--|
| Subject group type                | Reporting group     |  |  |  |
| Number of subjects analysed       | 379                 |  |  |  |
| Units: Percentage of participants |                     |  |  |  |
| number (confidence interval 95%)  |                     |  |  |  |
| Erythema                          | 12.1 (9.0 to 15.9)  |  |  |  |
| Pain                              | 61.2 (56.1 to 66.1) |  |  |  |
| Swelling                          | 7.7 (5.2 to 10.8)   |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants reporting each solicited systemic event (fever, headache, muscle pain, joint pain, tiredness)

|                 |  |
|-----------------|--|
| End point title | Percentage of participants reporting each solicited systemic event (fever, headache, muscle pain, joint pain, tiredness) |
|-----------------|--|

End point description:

Assessed solicited systemic events were arthralgia, fatigue, headache, myalgia and fever [temperature equal to or above ( $\geq$ ) 38 degrees Celsius ( $^{\circ}\text{C}$ )]. Any = occurrence of the symptom regardless of intensity grade or relation to study intervention.

Analysis was based on the Exposed Set (ES), which included all participants who received the study intervention and had data for solicited systemic events analysis at the assessed timeframe.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

During the 4-day follow up period after vaccination (vaccine or placebo administered on Day 1)

| End point values                  | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-----------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed       | 377                 | 191                     | 379                  | 189                      |
| Units: Percentage of participants |                     |                         |                      |                          |
| number (confidence interval 95%)  |                     |                         |                      |                          |
| Arthralgia                        | 26.0 (21.6 to 30.7) | 5.8 (2.9 to 10.1)       | 20.8 (16.9 to 25.3)  | 10.1 (6.2 to 15.3)       |
| Fatigue                           | 43.8 (38.7 to 48.9) | 17.3 (12.2 to 23.4)     | 35.9 (31.0 to 40.9)  | 19.0 (13.7 to 25.4)      |
| Headache                          | 35.8 (31.0 to 40.9) | 16.8 (11.8 to 22.8)     | 27.7 (23.3 to 32.5)  | 16.9 (11.9 to 23.1)      |
| Myalgia                           | 39.0 (34.0 to 44.1) | 5.8 (2.9 to 10.1)       | 32.2 (27.5 to 37.2)  | 13.8 (9.2 to 19.5)       |
| Fever                             | 3.7 (2.0 to 6.2)    | 1.0 (0.1 to 3.7)        | 2.6 (1.3 to 4.8)     | 1.1 (0.1 to 3.8)         |

| End point values                  | OA-RSV Group        |  |  |  |
|-----------------------------------|---------------------|--|--|--|
| Subject group type                | Reporting group     |  |  |  |
| Number of subjects analysed       | 379                 |  |  |  |
| Units: Percentage of participants |                     |  |  |  |
| number (confidence interval 95%)  |                     |  |  |  |
| Arthralgia                        | 12.9 (9.7 to 16.7)  |  |  |  |
| Fatigue                           | 23.7 (19.6 to 28.4) |  |  |  |
| Headache                          | 21.1 (17.1 to 25.6) |  |  |  |
| Myalgia                           | 21.1 (17.1 to 25.6) |  |  |  |
| Fever                             | 1.6 (0.6 to 3.4)    |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants reporting any unsolicited adverse events (AEs)

|   |   |
|---|---|
| End point title   | Percentage of participants reporting any unsolicited adverse events (AEs) |
| End point description:  |   |
| <p>Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.</p> <p>Analysis was based on the Exposed Set (ES), which included all participants who received the study intervention and had data for assessed timeframe and unsolicited events analysis.</p> |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| During the 30-day follow up period after vaccination (vaccine or placebo administered on Day 1)   |   |

| End point values                  | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-----------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed       | 383                 | 192                     | 386                  | 191                      |
| Units: Percentage of participants |                     |                         |                      |                          |
| number (confidence interval 95%)  | 13.1 (9.8 to 16.8)  | 13.5 (9.0 to 19.2)      | 14.8 (11.4 to 18.7)  | 9.9 (6.1 to 15.1)        |

| End point values                  | OA-RSV Group        |  |  |  |
|-----------------------------------|---------------------|--|--|--|
| Subject group type                | Reporting group     |  |  |  |
| Number of subjects analysed       | 381                 |  |  |  |
| Units: Percentage of participants |                     |  |  |  |
| number (confidence interval 95%)  | 16.3 (12.7 to 20.4) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants reporting any serious adverse events (SAEs)

|                 |  |
|-----------------|--|
| End point title | Percentage of participants reporting any serious adverse events (SAEs) |
|-----------------|--|

End point description:

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

Analysis was based on the ES, which included all participants who received the study intervention. Analysis per group is based on the administered intervention.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the day of the vaccination (Day 1) up to 6 months post dose (Month 6)

| End point values                  | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-----------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed       | 383                 | 192                     | 386                  | 191                      |
| Units: Percentage of participants |                     |                         |                      |                          |
| number (confidence interval 95%)  | 0.5 (0.1 to 1.9)    | 2.1 (0.6 to 5.2)        | 3.6 (2.0 to 6.0)     | 2.1 (0.6 to 5.3)         |

| End point values                  | OA-RSV Group     |  |  |  |
|-----------------------------------|------------------|--|--|--|
| Subject group type                | Reporting group  |  |  |  |
| Number of subjects analysed       | 381              |  |  |  |
| Units: Percentage of participants |                  |  |  |  |
| number (confidence interval 95%)  | 2.4 (1.1 to 4.4) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants reporting any potential immune mediated diseases (pIMDs)

|                 |   |
|-----------------|---|
| End point title | Percentage of participants reporting any potential immune mediated diseases (pIMDs) |
|-----------------|---|

End point description:

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Analysis was based on the ES, which included all participants who received the study intervention.

Analysis per group is based on the administered intervention.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the day of the vaccination (Day 1) up to 6 months post dose (Month 6)

| End point values                  | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-----------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed       | 383                 | 192                     | 386                  | 191                      |
| Units: Percentage of participants |                     |                         |                      |                          |
| number (confidence interval 95%)  | 0 (0 to 0)          | 0 (0 to 0)              | 1.0 (0.3 to 2.6)     | 0.5 (0.0 to 2.9)         |

| End point values                  | OA-RSV Group     |  |  |  |
|-----------------------------------|------------------|--|--|--|
| Subject group type                | Reporting group  |  |  |  |
| Number of subjects analysed       | 381              |  |  |  |
| Units: Percentage of participants |                  |  |  |  |
| number (confidence interval 95%)  | 0.8 (0.2 to 2.3) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants reporting SAEs related to study intervention administration

|  |  |
|--|--|
| End point title  | Percentage of participants reporting SAEs related to study intervention administration |
| End point description:<br>An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome. |  |
| End point type   | Secondary  |
| End point timeframe:<br>From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)   |  |

| End point values                  | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-----------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed       | 0 <sup>[9]</sup>    | 0 <sup>[10]</sup>       | 0 <sup>[11]</sup>    | 0 <sup>[12]</sup>        |
| Units: Percentage of participants |                     |                         |                      |                          |
| number (confidence interval 95%)  | ( to )              | ( to )                  | ( to )               | ( to )                   |

Notes:

- [9] - Data for this analysis will be updated at the time of final posting.  
[10] - Data for this analysis will be updated at the time of final posting.  
[11] - Data for this analysis will be updated at the time of final posting.  
[12] - Data for this analysis will be updated at the time of final posting.

| End point values                  | OA-RSV Group      |  |  |  |
|-----------------------------------|-------------------|--|--|--|
| Subject group type                | Reporting group   |  |  |  |
| Number of subjects analysed       | 0 <sup>[13]</sup> |  |  |  |
| Units: Percentage of participants |                   |  |  |  |
| number (confidence interval 95%)  | ( to )            |  |  |  |

Notes:

- [13] - Data for this analysis will be updated at the time of final posting.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants reporting pIMDs related to study intervention administration

|  |   |
|--|---|
| End point title  | Percentage of participants reporting pIMDs related to study intervention administration |
| End point description:<br>pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Analysis was based on the ES, which included all participants who received the study intervention. Analysis per group is based on the administered intervention. |   |
| End point type   | Secondary   |
| End point timeframe:<br>From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)   |   |

| End point values                  | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-----------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed       | 0 <sup>[14]</sup>   | 0 <sup>[15]</sup>       | 0 <sup>[16]</sup>    | 0 <sup>[17]</sup>        |
| Units: Percentage of participants |                     |                         |                      |                          |
| number (confidence interval 95%)  | ( to )              | ( to )                  | ( to )               | ( to )                   |

Notes:

[14] - Data for this analysis will be updated at the time of final posting.

[15] - Data for this analysis will be updated at the time of final posting.

[16] - Data for this analysis will be updated at the time of final posting.

[17] - Data for this analysis will be updated at the time of final posting.

| End point values                  | OA-RSV Group      |  |  |  |
|-----------------------------------|-------------------|--|--|--|
| Subject group type                | Reporting group   |  |  |  |
| Number of subjects analysed       | 0 <sup>[18]</sup> |  |  |  |
| Units: Percentage of participants |                   |  |  |  |
| number (confidence interval 95%)  | ( to )            |  |  |  |

Notes:

[18] - Data for this analysis will be updated at the time of final posting.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants reporting any fatal SAEs

|                 |   |
|-----------------|---|
| End point title | Percentage of participants reporting any fatal SAEs |
|-----------------|---|

End point description:

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or results in an abnormal pregnancy outcome.

Analysis was based on the ES, which included all participants who received the study intervention.

Analysis per group is based on the administered intervention.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the day of the vaccination up to 12 months after vaccination (vaccine or placebo administered on Day 1)

| End point values                  | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-----------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed       | 0 <sup>[19]</sup>   | 0 <sup>[20]</sup>       | 0 <sup>[21]</sup>    | 0 <sup>[22]</sup>        |
| Units: Percentage of participants |                     |                         |                      |                          |
| number (confidence interval 95%)  | ( to )              | ( to )                  | ( to )               | ( to )                   |

Notes:

[19] - Data for this analysis will be updated at the time of final posting.

[20] - Data for this analysis will be updated at the time of final posting.

[21] - Data for this analysis will be updated at the time of final posting.

[22] - Data for this analysis will be updated at the time of final posting.

| End point values                  | OA-RSV Group      |  |  |  |
|-----------------------------------|-------------------|--|--|--|
| Subject group type                | Reporting group   |  |  |  |
| Number of subjects analysed       | 0 <sup>[23]</sup> |  |  |  |
| Units: Percentage of participants |                   |  |  |  |
| number (confidence interval 95%)  | ( to )            |  |  |  |

Notes:

[23] - Data for this analysis will be updated at the time of final posting.

## Statistical analyses

No statistical analyses for this end point

## Secondary: RSV-A neutralization titers expressed as GMT, up to one month post-intervention

|                 |   |
|-----------------|---|
| End point title | RSV-A neutralization titers expressed as GMT, up to one month post-intervention |
|-----------------|---|

End point description:

Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA\_RSV, Adults HA-Placebo, Adult AIR\_RSV, Adult AIR\_Placebo and OA\_RSV groups.

Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for the assessed analysis, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

| End point values                         | Adults HA-RSV Group       | Adults HA-Placebo Group | Adults AIR-RSV Group      | Adults AIR-Placebo Group |
|--|---------------------------|-------------------------|---------------------------|--------------------------|
| Subject group type                       | Reporting group           | Reporting group         | Reporting group           | Reporting group          |
| Number of subjects analysed              | 347                       | 181                     | 365                       | 186                      |
| Units: Titer                             |                           |                         |                           |                          |
| geometric mean (confidence interval 95%) |                           |                         |                           |                          |
| Day 1                                    | 768.8 (704.7 to 838.9)    | 772.0 (677.9 to 879.1)  | 781.7 (727.5 to 840.0)    | 729.8 (648.6 to 821.0)   |
| Day 31                                   | 7925.4 (7125.6 to 8815.0) | 796.9 (696.4 to 912.0)  | 8821.9 (7971.0 to 9763.6) | 774.9 (683.7 to 878.3)   |

| End point values | OA-RSV Group |  |  |  |
|------------------|--------------|--|--|--|
|------------------|--------------|--|--|--|



|  |                           |  |  |  |
|--|---------------------------|--|--|--|
| Subject group type                       | Reporting group           |  |  |  |
| Number of subjects analysed              | 362                       |  |  |  |
| Units: Titer                             |                           |  |  |  |
| geometric mean (confidence interval 95%) |                           |  |  |  |
| Day 1                                    | 772.2 (706.6 to 843.8)    |  |  |  |
| Day 31                                   | 7461.9 (6724.9 to 8279.6) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: RSV-A neutralization titers expressed as GMT at Month 6 and Month 12 post-intervention

|                 |  |
|-----------------|--|
| End point title | RSV-A neutralization titers expressed as GMT at Month 6 and Month 12 post-intervention |
|-----------------|--|

End point description:

Serological assays for the determination of antibodies against RSV-A are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 6 months and at 12 months after study intervention administration

| End point values                         | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|--|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                       | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed              | 0 <sup>[24]</sup>   | 0 <sup>[25]</sup>       | 0 <sup>[26]</sup>    | 0 <sup>[27]</sup>        |
| Units: Titer                             |                     |                         |                      |                          |
| geometric mean (confidence interval 95%) | ( to )              | ( to )                  | ( to )               | ( to )                   |

Notes:

[24] - Data for this analysis will be updated at the time of final posting.

[25] - Data for this analysis will be updated at the time of final posting.

[26] - Data for this analysis will be updated at the time of final posting.

[27] - Data for this analysis will be updated at the time of final posting.

| End point values                         | OA-RSV Group      |  |  |  |
|--|-------------------|--|--|--|
| Subject group type                       | Reporting group   |  |  |  |
| Number of subjects analysed              | 0 <sup>[28]</sup> |  |  |  |
| Units: Titer                             |                   |  |  |  |
| geometric mean (confidence interval 95%) | ( to )            |  |  |  |

Notes:

[28] - Data for this analysis will be updated at the time of final posting.

## Statistical analyses

No statistical analyses for this end point

### Secondary: RSV-B neutralization titers expressed as GMT, up to one month post-intervention

|                 |   |
|-----------------|---|
| End point title | RSV-B neutralization titers expressed as GMT, up to one month post-intervention |
|-----------------|---|

End point description:

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Unadjusted GMTs were provided for Adult HA\_RSV, Adults HA-Placebo, Adult AIR\_RSV, Adult AIR\_Placebo and OA\_RSV groups.

Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Analysis per group is based on the administered intervention.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

| End point values                         | Adults HA-RSV Group       | Adults HA-Placebo Group   | Adults AIR-RSV Group       | Adults AIR-Placebo Group  |
|--|---------------------------|---------------------------|----------------------------|---------------------------|
| Subject group type                       | Reporting group           | Reporting group           | Reporting group            | Reporting group           |
| Number of subjects analysed              | 347                       | 181                       | 365                        | 186                       |
| Units: Titer                             |                           |                           |                            |                           |
| geometric mean (confidence interval 95%) |                           |                           |                            |                           |
| Day 1                                    | 1091.1 (1000.3 to 1190.2) | 1197.7 (1055.7 to 1358.8) | 1141.6 (1051.0 to 1240.0)  | 1167.2 (1035.0 to 1316.1) |
| Day 31                                   | 8971.9 (8109.6 to 9925.8) | 1145.3 (1012.4 to 1295.5) | 9967.3 (9059.3 to 10966.3) | 1141.7 (1007.9 to 1293.1) |

| End point values                         | OA-RSV Group    |  |  |  |
|--|-----------------|--|--|--|
| Subject group type                       | Reporting group |  |  |  |
| Number of subjects analysed              | 362             |  |  |  |
| Units: Titer                             |                 |  |  |  |
| geometric mean (confidence interval 95%) |                 |  |  |  |

|        |                           |  |  |  |
|--------|---------------------------|--|--|--|
| Day 1  | 1104.2 (1016.2 to 1199.9) |  |  |  |
| Day 31 | 8144.5 (7388.9 to 8977.4) |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: RSV-B neutralization titers expressed as GMT, at Month 6 and Month 12 post-intervention

|                 |   |
|-----------------|---|
| End point title | RSV-B neutralization titers expressed as GMT, at Month 6 and Month 12 post-intervention |
|-----------------|---|

End point description:

Serological assays for the determination of antibodies against RSV-B are performed by neutralization assay. The corresponding antibody titers were expressed in ED60. Analysis was performed on PPS for humoral analysis which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for the assessed analysis, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 6 months and at 12 months after study intervention administration

| End point values                         | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|--|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                       | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed              | 0 <sup>[29]</sup>   | 0 <sup>[30]</sup>       | 0 <sup>[31]</sup>    | 0 <sup>[32]</sup>        |
| Units: Titer                             |                     |                         |                      |                          |
| geometric mean (confidence interval 95%) | ( to )              | ( to )                  | ( to )               | ( to )                   |

Notes:

[29] - Data for this analysis will be updated at the time of final posting.

[30] - Data for this analysis will be updated at the time of final posting.

[31] - Data for this analysis will be updated at the time of final posting.

[32] - Data for this analysis will be updated at the time of final posting.

| End point values                         | OA-RSV Group      |  |  |  |
|--|-------------------|--|--|--|
| Subject group type                       | Reporting group   |  |  |  |
| Number of subjects analysed              | 0 <sup>[33]</sup> |  |  |  |
| Units: Titer                             |                   |  |  |  |
| geometric mean (confidence interval 95%) | ( to )            |  |  |  |

Notes:

[33] - Data for this analysis will be updated at the time of final posting.

## Statistical analyses

**Secondary: Frequency of RSVPreF3-specific cluster of differentiation (CD)4+ T cells expressing at least 2 activation markers, up to one month post-intervention**

|                 |  |
|-----------------|--|
| End point title | Frequency of RSVPreF3-specific cluster of differentiation (CD)4+ T cells expressing at least 2 activation markers, up to one month post-intervention |
|-----------------|--|

## End point description:

Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Analysis was performed on Cell-Mediated immune (CMI) sub-cohort of the PPS, which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for RSVPreF3 OA specific CD4+ T cells, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

At pre-study intervention administration (Day 1) and 1 months after study intervention administration (Day 31)

| End point values                    | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-------------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                  | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed         | 47                  | 28                      | 55                   | 27                       |
| Units: CD4+ T cells/million cells   |                     |                         |                      |                          |
| geometric mean (standard deviation) |                     |                         |                      |                          |
| Day 1                               | 102.7 (± 0.9)       | 125.6 (± 0.9)           | 161.5 (± 0.6)        | 114.7 (± 0.9)            |
| Day 31                              | 1282.5 (± 0.4)      | 167.7 (± 0.8)           | 1043.6 (± 0.6)       | 131.9 (± 0.8)            |

| End point values                    | OA-RSV Group    |  |  |  |
|-------------------------------------|-----------------|--|--|--|
| Subject group type                  | Reporting group |  |  |  |
| Number of subjects analysed         | 25              |  |  |  |
| Units: CD4+ T cells/million cells   |                 |  |  |  |
| geometric mean (standard deviation) |                 |  |  |  |
| Day 1                               | 108.8 (± 0.9)   |  |  |  |
| Day 31                              | 1029.2 (± 0.8)  |  |  |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Frequency of RSVPreF3-specific CD4+ T cells expressing at least 2 activation markers, at Month 6 and Month 12 post-intervention**

|                 |   |
|-----------------|---|
| End point title | Frequency of RSVPreF3-specific CD4+ T cells expressing at least 2 activation markers, at Month 6 and Month 12 post-intervention |
|-----------------|---|

**End point description:**

Among markers expressed are interleukin-2/13/17 (IL-2, IL-13, IL-17), cluster of 40 ligand (CD40L), 41BB, tumour necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Analysis was performed on Cell-Mediated immune (CMI) sub-cohort of the PPS, which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for RSVPreF3 OA specific CD4+ T cells, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

**End point timeframe:**

At 6 months and at 12 months after study intervention administration

| End point values                    | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-------------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                  | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed         | 0 <sup>[34]</sup>   | 0 <sup>[35]</sup>       | 0 <sup>[36]</sup>    | 0 <sup>[37]</sup>        |
| Units: CD4+ T cells/million cells   |                     |                         |                      |                          |
| geometric mean (standard deviation) | ()                  | ()                      | ()                   | ()                       |

**Notes:**

[34] - Data for this analysis will be updated at the time of final posting.

[35] - Data for this analysis will be updated at the time of final posting.

[36] - Data for this analysis will be updated at the time of final posting.

[37] - Data for this analysis will be updated at the time of final posting.

| End point values                    | OA-RSV Group      |  |  |  |
|-------------------------------------|-------------------|--|--|--|
| Subject group type                  | Reporting group   |  |  |  |
| Number of subjects analysed         | 0 <sup>[38]</sup> |  |  |  |
| Units: CD4+ T cells/million cells   |                   |  |  |  |
| geometric mean (standard deviation) | ()                |  |  |  |

**Notes:**

[38] - Data for this analysis will be updated at the time of final posting.

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers, up to one month post-intervention**

|                 |   |
|-----------------|---|
| End point title | Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers, up to one month post-intervention |
|-----------------|---|

**End point description:**

Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Analysis was performed on Cell-Mediated immune (CMI) sub-cohort of the PPS, which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for RSVPreF3 OA specific CD8+ T cells, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

**End point timeframe:**

At pre-study intervention administration (Day 1) and 1 month after study intervention administration (Day 31)

| End point values                    | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-------------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                  | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed         | 46                  | 28                      | 55                   | 27                       |
| Units: CD8+ T cells/million cells   |                     |                         |                      |                          |
| geometric mean (standard deviation) |                     |                         |                      |                          |
| Day 1                               | 10.1 (± 1.1)        | 6.0 (± 0.9)             | 15.5 (± 1.0)         | 10.8 (± 1.1)             |
| Day 31                              | 15.2 (± 1.1)        | 11.9 (± 1.1)            | 18.1 (± 1.1)         | 4.8 (± 1.1)              |

| End point values                    | OA-RSV Group    |  |  |  |
|-------------------------------------|-----------------|--|--|--|
| Subject group type                  | Reporting group |  |  |  |
| Number of subjects analysed         | 25              |  |  |  |
| Units: CD8+ T cells/million cells   |                 |  |  |  |
| geometric mean (standard deviation) |                 |  |  |  |
| Day 1                               | 13.2 (± 1.0)    |  |  |  |
| Day 31                              | 13.3 (± 1.2)    |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers, at Month 6 and Month 12 post-intervention

|                 |   |
|-----------------|---|
| End point title | Frequency of RSVPreF3-specific CD8+ T cells expressing at least 2 activation markers, at Month 6 and Month 12 post-intervention |
|-----------------|---|

End point description:

Among markers expressed are IL-2, IL-13, IL-17, CD40L, 41BB, TNF-α and IFN-γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

Analysis was performed on Cell-Mediated immune (CMI) sub-cohort of the PPS, which included all eligible participants who received the study intervention as per protocol, had immunogenicity results pre- and post-dose for RSVPreF3 OA specific CD8+ T cells, complied with blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 6 months and at 12 months after study intervention administration

| End point values                    | Adults HA-RSV Group | Adults HA-Placebo Group | Adults AIR-RSV Group | Adults AIR-Placebo Group |
|-------------------------------------|---------------------|-------------------------|----------------------|--------------------------|
| Subject group type                  | Reporting group     | Reporting group         | Reporting group      | Reporting group          |
| Number of subjects analysed         | 0 <sup>[39]</sup>   | 0 <sup>[40]</sup>       | 0 <sup>[41]</sup>    | 0 <sup>[42]</sup>        |
| Units: CD8+ T cells/million cells   |                     |                         |                      |                          |
| geometric mean (standard deviation) | ()                  | ()                      | ()                   | ()                       |

Notes:

[39] - Data for this analysis will be updated at the time of final posting.

[40] - Data for this analysis will be updated at the time of final posting.

[41] - Data for this analysis will be updated at the time of final posting.

[42] - Data for this analysis will be updated at the time of final posting.

| End point values                    | OA-RSV Group      |  |  |  |
|-------------------------------------|-------------------|--|--|--|
| Subject group type                  | Reporting group   |  |  |  |
| Number of subjects analysed         | 0 <sup>[43]</sup> |  |  |  |
| Units: CD8+ T cells/million cells   |                   |  |  |  |
| geometric mean (standard deviation) | ()                |  |  |  |

Notes:

[43] - Data for this analysis will be updated at the time of final posting.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

SAEs were reported from Day 1 (day of vaccination) until Month 6 post-dose administration. Solicited and unsolicited AEs were reported from Day 1 up to 30 days post dose administration.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |       |
|--------------------|-------|
| Dictionary version | v26.0 |
|--------------------|-------|

### Reporting groups

|                       |                     |
|-----------------------|---------------------|
| Reporting group title | Adults HA-RSV Group |
|-----------------------|---------------------|

Reporting group description:

Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

|                       |                         |
|-----------------------|-------------------------|
| Reporting group title | Adults HA-Placebo Group |
|-----------------------|-------------------------|

Reporting group description:

Healthy adults or adults with chronic stable conditions with or without treatment that do not lead to an increased risk of RSV-LRTD, aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

|                       |              |
|-----------------------|--------------|
| Reporting group title | OA-RSV Group |
|-----------------------|--------------|

Reporting group description:

Older adults aged 60 years old and above received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

|                       |                          |
|-----------------------|--------------------------|
| Reporting group title | Adults AIR-Placebo Group |
|-----------------------|--------------------------|

Reporting group description:

Adults at increased risk of RSV-LRTD aged 50-59 years old received 1 dose of placebo at Day 1 and were followed until study end.

|                       |                      |
|-----------------------|----------------------|
| Reporting group title | Adults AIR-RSV Group |
|-----------------------|----------------------|

Reporting group description:

Adults at increased risk of RSV-Lower respiratory tract disease (RSV-LRTD) aged 50-59 years old received 1 dose of RSVPreF3 OA vaccine at Day 1 and were followed until study end.

| Serious adverse events  | Adults HA-RSV Group | Adults HA-Placebo Group | OA-RSV Group    |
|---|---------------------|-------------------------|-----------------|
| Total subjects affected by serious adverse events                   |                     |                         |                 |
| subjects affected / exposed   | 2 / 383 (0.52%)     | 4 / 192 (2.08%)         | 9 / 381 (2.36%) |
| number of deaths (all causes)                                       | 0                   | 0                       | 0               |
| number of deaths resulting from adverse events                      |                     |                         |                 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                     |                         |                 |
| Adenocarcinoma of colon   |                     |                         |                 |
| subjects affected / exposed   | 1 / 383 (0.26%)     | 0 / 192 (0.00%)         | 1 / 381 (0.26%) |
| occurrences causally related to treatment / all                     | 0 / 1               | 0 / 0                   | 0 / 1           |
| deaths causally related to treatment / all                          | 0 / 0               | 0 / 0                   | 0 / 0           |
| Breast cancer   |                     |                         |                 |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 383 (0.00%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                 |                 |
| Femur fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 383 (0.26%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Alcohol poisoning                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hip fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Kyphosis postoperative                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |
| Pericarditis                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Atrial fibrillation                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| Cerebellar stroke                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Cerebrovascular accident                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Blood and lymphatic system disorders            |                 |                 |                 |
| Cold type haemolytic anaemia                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |
| Inguinal hernia                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                 |                 |                 |
| Non-alcoholic fatty liver                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders |                 |                 |                 |
| Chronic obstructive pulmonary disease           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Asthma  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Acute respiratory failure                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychiatric disorders                           |                 |                 |                 |
| Depression                                      |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                                   | 0 / 383 (0.00%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders               |                 |                 |                 |
| Gouty arthritis   |                 |                 |                 |
| subjects affected / exposed                                   | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Osteoarthritis  |                 |                 |                 |
| subjects affected / exposed                                   | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                                   |                 |                 |                 |
| Abscess oral  |                 |                 |                 |
| subjects affected / exposed                                   | 0 / 383 (0.00%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Osteomyelitis   |                 |                 |                 |
| subjects affected / exposed                                   | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Infective exacerbation of chronic obstructive airways disease |                 |                 |                 |
| subjects affected / exposed                                   | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           | 0 / 0           |
| Cellulitis  |                 |                 |                 |
| subjects affected / exposed                                   | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           | 0 / 0           |
| COVID-19  |                 |                 |                 |
| subjects affected / exposed                                   | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           | 0 / 0           |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Pneumonia                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 2 / 381 (0.52%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Acute sinusitis                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Enterococcal bacteraemia                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Metabolism and nutrition disorders              |                 |                 |                 |
| Obesity   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 383 (0.00%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                                       | Adults AIR-Placebo Group | Adults AIR-RSV Group |  |
|---|--------------------------|----------------------|--|
| Total subjects affected by serious adverse events                   |                          |                      |  |
| subjects affected / exposed   | 4 / 191 (2.09%)          | 14 / 386 (3.63%)     |  |
| number of deaths (all causes)                                       | 0                        | 0                    |  |
| number of deaths resulting from adverse events                      |                          |                      |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                          |                      |  |
| Adenocarcinoma of colon   |                          |                      |  |
| subjects affected / exposed   | 0 / 191 (0.00%)          | 0 / 386 (0.00%)      |  |
| occurrences causally related to treatment / all                     | 0 / 0                    | 0 / 0                |  |
| deaths causally related to treatment / all                          | 0 / 0                    | 0 / 0                |  |
| Breast cancer   |                          |                      |  |
| subjects affected / exposed   | 0 / 191 (0.00%)          | 0 / 386 (0.00%)      |  |
| occurrences causally related to treatment / all                     | 0 / 0                    | 0 / 0                |  |
| deaths causally related to treatment / all                          | 0 / 0                    | 0 / 0                |  |
| Injury, poisoning and procedural complications                      |                          |                      |  |
| Femur fracture  |                          |                      |  |

|   |                 |                 |  |
|---|-----------------|-----------------|--|
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Alcohol poisoning                               |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Hip fracture                                    |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Kyphosis postoperative                          |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Cardiac disorders                               |                 |                 |  |
| Pericarditis                                    |                 |                 |  |
| subjects affected / exposed                     | 1 / 191 (0.52%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Atrial fibrillation                             |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Nervous system disorders                        |                 |                 |  |
| Cerebellar stroke                               |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Cerebrovascular accident                        |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Blood and lymphatic system disorders            |                 |                 |  |

|   |                 |                 |  |
|---|-----------------|-----------------|--|
| Cold type haemolytic anaemia<br>subjects affected / exposed             | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences causally related to<br>treatment / all                      | 0 / 0           | 0 / 0           |  |
| deaths causally related to<br>treatment / all                           | 0 / 0           | 0 / 0           |  |
| Gastrointestinal disorders  |                 |                 |  |
| Inguinal hernia<br>subjects affected / exposed                          | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences causally related to<br>treatment / all                      | 0 / 0           | 0 / 0           |  |
| deaths causally related to<br>treatment / all                           | 0 / 0           | 0 / 0           |  |
| Hepatobiliary disorders   |                 |                 |  |
| Non-alcoholic fatty liver<br>subjects affected / exposed                | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to<br>treatment / all                      | 0 / 0           | 0 / 1           |  |
| deaths causally related to<br>treatment / all                           | 0 / 0           | 0 / 0           |  |
| Respiratory, thoracic and mediastinal<br>disorders                      |                 |                 |  |
| Chronic obstructive pulmonary<br>disease<br>subjects affected / exposed | 0 / 191 (0.00%) | 2 / 386 (0.52%) |  |
| occurrences causally related to<br>treatment / all                      | 0 / 0           | 0 / 2           |  |
| deaths causally related to<br>treatment / all                           | 0 / 0           | 0 / 0           |  |
| Asthma<br>subjects affected / exposed                                   | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to<br>treatment / all                      | 0 / 0           | 0 / 1           |  |
| deaths causally related to<br>treatment / all                           | 0 / 0           | 0 / 0           |  |
| Acute respiratory failure<br>subjects affected / exposed                | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to<br>treatment / all                      | 0 / 0           | 0 / 1           |  |
| deaths causally related to<br>treatment / all                           | 0 / 0           | 0 / 0           |  |
| Psychiatric disorders   |                 |                 |  |
| Depression<br>subjects affected / exposed                               | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to<br>treatment / all                      | 0 / 0           | 0 / 1           |  |
| deaths causally related to<br>treatment / all                           | 0 / 0           | 0 / 0           |  |
| Musculoskeletal and connective tissue<br>disorders                      |                 |                 |  |

|   |                 |                 |  |
|---|-----------------|-----------------|--|
| Gouty arthritis   |                 |                 |  |
| subjects affected / exposed                                   | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           |  |
| Osteoarthritis  |                 |                 |  |
| subjects affected / exposed                                   | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           |  |
| Infections and infestations                                   |                 |                 |  |
| Abscess oral  |                 |                 |  |
| subjects affected / exposed                                   | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 0           |  |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           |  |
| Osteomyelitis   |                 |                 |  |
| subjects affected / exposed                                   | 1 / 191 (0.52%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all               | 0 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           |  |
| Infective exacerbation of chronic obstructive airways disease |                 |                 |  |
| subjects affected / exposed                                   | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           |  |
| Cellulitis  |                 |                 |  |
| subjects affected / exposed                                   | 1 / 191 (0.52%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all               | 0 / 1           | 0 / 1           |  |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           |  |
| COVID-19  |                 |                 |  |
| subjects affected / exposed                                   | 1 / 191 (0.52%) | 0 / 386 (0.00%) |  |
| occurrences causally related to treatment / all               | 0 / 1           | 0 / 0           |  |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           |  |
| Pneumonia   |                 |                 |  |
| subjects affected / exposed                                   | 0 / 191 (0.00%) | 3 / 386 (0.78%) |  |
| occurrences causally related to treatment / all               | 0 / 0           | 0 / 3           |  |
| deaths causally related to treatment / all                    | 0 / 0           | 0 / 0           |  |

|   |                 |                 |  |
|---|-----------------|-----------------|--|
| Acute sinusitis                                 |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Enterococcal bacteraemia                        |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |
| Metabolism and nutrition disorders              |                 |                 |  |
| Obesity   |                 |                 |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           |  |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           |  |

Frequency threshold for reporting non-serious adverse events: 0 %

| <b>Non-serious adverse events</b>                                   | Adults HA-RSV Group | Adults HA-Placebo Group | OA-RSV Group       |
|---|---------------------|-------------------------|--------------------|
| Total subjects affected by non-serious adverse events               |                     |                         |                    |
| subjects affected / exposed   | 323 / 383 (84.33%)  | 76 / 192 (39.58%)       | 278 / 381 (72.97%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                     |                         |                    |
| Uterine leiomyoma   |                     |                         |                    |
| subjects affected / exposed   | 1 / 383 (0.26%)     | 0 / 192 (0.00%)         | 0 / 381 (0.00%)    |
| occurrences (all)   | 1                   | 0                       | 0                  |
| Breast cancer   |                     |                         |                    |
| subjects affected / exposed   | 0 / 383 (0.00%)     | 0 / 192 (0.00%)         | 0 / 381 (0.00%)    |
| occurrences (all)   | 0                   | 0                       | 0                  |
| Vascular disorders  |                     |                         |                    |
| Hypertension  |                     |                         |                    |
| subjects affected / exposed   | 0 / 383 (0.00%)     | 0 / 192 (0.00%)         | 1 / 381 (0.26%)    |
| occurrences (all)   | 0                   | 0                       | 1                  |
| General disorders and administration site conditions                |                     |                         |                    |
| Administration site bruise  |                     |                         |                    |
| subjects affected / exposed   | 0 / 383 (0.00%)     | 0 / 192 (0.00%)         | 0 / 381 (0.00%)    |
| occurrences (all)   | 0                   | 0                       | 0                  |
| Administration site warmth  |                     |                         |                    |



|                             |                    |                   |                    |
|-----------------------------|--------------------|-------------------|--------------------|
| subjects affected / exposed | 0 / 383 (0.00%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)    |
| occurrences (all)           | 0                  | 0                 | 0                  |
| Injection site pruritus     |                    |                   |                    |
| subjects affected / exposed | 3 / 383 (0.78%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)    |
| occurrences (all)           | 3                  | 0                 | 0                  |
| Injection site pain         |                    |                   |                    |
| subjects affected / exposed | 288 / 383 (75.20%) | 20 / 192 (10.42%) | 233 / 381 (61.15%) |
| occurrences (all)           | 288                | 20                | 233                |
| Injection site induration   |                    |                   |                    |
| subjects affected / exposed | 1 / 383 (0.26%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)    |
| occurrences (all)           | 1                  | 0                 | 0                  |
| Injection site erythema     |                    |                   |                    |
| subjects affected / exposed | 40 / 383 (10.44%)  | 1 / 192 (0.52%)   | 42 / 381 (11.02%)  |
| occurrences (all)           | 40                 | 1                 | 42                 |
| Injection site bruising     |                    |                   |                    |
| subjects affected / exposed | 0 / 383 (0.00%)    | 0 / 192 (0.00%)   | 1 / 381 (0.26%)    |
| occurrences (all)           | 0                  | 0                 | 1                  |
| Influenza like illness      |                    |                   |                    |
| subjects affected / exposed | 1 / 383 (0.26%)    | 1 / 192 (0.52%)   | 2 / 381 (0.52%)    |
| occurrences (all)           | 1                  | 1                 | 2                  |
| Fatigue                     |                    |                   |                    |
| subjects affected / exposed | 165 / 383 (43.08%) | 34 / 192 (17.71%) | 91 / 381 (23.88%)  |
| occurrences (all)           | 166                | 34                | 91                 |
| Chills                      |                    |                   |                    |
| subjects affected / exposed | 2 / 383 (0.52%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)    |
| occurrences (all)           | 2                  | 0                 | 0                  |
| Chest pain                  |                    |                   |                    |
| subjects affected / exposed | 1 / 383 (0.26%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)    |
| occurrences (all)           | 1                  | 0                 | 0                  |
| Asthenia                    |                    |                   |                    |
| subjects affected / exposed | 1 / 383 (0.26%)    | 0 / 192 (0.00%)   | 3 / 381 (0.79%)    |
| occurrences (all)           | 1                  | 0                 | 3                  |
| Injection site swelling     |                    |                   |                    |
| subjects affected / exposed | 32 / 383 (8.36%)   | 2 / 192 (1.04%)   | 25 / 381 (6.56%)   |
| occurrences (all)           | 32                 | 2                 | 25                 |
| Peripheral swelling         |                    |                   |                    |

|   |                        |                      |                      |
|---|------------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 383 (0.00%)<br>0   | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)   | 14 / 383 (3.66%)<br>14 | 2 / 192 (1.04%)<br>2 | 7 / 381 (1.84%)<br>7 |
| Reproductive system and breast disorders<br>Dysmenorrhoea<br>subjects affected / exposed<br>occurrences (all) | 0 / 383 (0.00%)<br>0   | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Respiratory, thoracic and mediastinal disorders<br>Asthma<br>subjects affected / exposed<br>occurrences (all) | 0 / 383 (0.00%)<br>0   | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)  | 0 / 383 (0.00%)<br>0   | 1 / 192 (0.52%)<br>1 | 1 / 381 (0.26%)<br>1 |
| Bronchospasm<br>subjects affected / exposed<br>occurrences (all)  | 1 / 383 (0.26%)<br>1   | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Chronic obstructive pulmonary disease<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 383 (0.00%)<br>0   | 0 / 192 (0.00%)<br>0 | 2 / 381 (0.52%)<br>2 |
| Cough<br>subjects affected / exposed<br>occurrences (all)   | 3 / 383 (0.78%)<br>3   | 0 / 192 (0.00%)<br>0 | 2 / 381 (0.52%)<br>2 |
| Sinus congestion<br>subjects affected / exposed<br>occurrences (all)  | 0 / 383 (0.00%)<br>0   | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Rhinorrhoea<br>subjects affected / exposed<br>occurrences (all)   | 3 / 383 (0.78%)<br>3   | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Oropharyngeal pain<br>subjects affected / exposed<br>occurrences (all)  | 2 / 383 (0.52%)<br>2   | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Nasal congestion  |                        |                      |                      |

|   |                      |                      |                      |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Epistaxis<br>subjects affected / exposed<br>occurrences (all)   | 1 / 383 (0.26%)<br>1 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Throat irritation<br>subjects affected / exposed<br>occurrences (all)   | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                            | 2 / 383 (0.52%)<br>2 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Insomnia<br>subjects affected / exposed<br>occurrences (all)  | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Investigations<br>Blood pressure increased<br>subjects affected / exposed<br>occurrences (all)                  | 1 / 383 (0.26%)<br>1 | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Helicobacter test positive<br>subjects affected / exposed<br>occurrences (all)                                  | 1 / 383 (0.26%)<br>1 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Injury, poisoning and procedural complications<br>Contusion<br>subjects affected / exposed<br>occurrences (all) | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Immunisation reaction<br>subjects affected / exposed<br>occurrences (all)                                       | 1 / 383 (0.26%)<br>1 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Meniscus injury<br>subjects affected / exposed<br>occurrences (all)   | 0 / 383 (0.00%)<br>0 | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Post-traumatic pain<br>subjects affected / exposed<br>occurrences (all)   | 1 / 383 (0.26%)<br>1 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Soft tissue injury  |                      |                      |                      |

|  |                      |                      |                      |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)                                 | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Rib fracture<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 383 (0.26%)<br>1 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Cardiac disorders  |                      |                      |                      |
| Angina pectoris<br>subjects affected / exposed<br>occurrences (all)              | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Atrial fibrillation<br>subjects affected / exposed<br>occurrences (all)          | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Supraventricular tachycardia<br>subjects affected / exposed<br>occurrences (all) | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Palpitations<br>subjects affected / exposed<br>occurrences (all)                 | 1 / 383 (0.26%)<br>1 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Cardiac failure chronic<br>subjects affected / exposed<br>occurrences (all)      | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Cardiac failure<br>subjects affected / exposed<br>occurrences (all)              | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Nervous system disorders   |                      |                      |                      |
| Carotid arteriosclerosis<br>subjects affected / exposed<br>occurrences (all)     | 0 / 383 (0.00%)<br>0 | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Taste disorder<br>subjects affected / exposed<br>occurrences (all)               | 0 / 383 (0.00%)<br>0 | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Sinus headache<br>subjects affected / exposed<br>occurrences (all)               | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Sciatica   |                      |                      |                      |

|                                      |                    |                   |                   |
|--------------------------------------|--------------------|-------------------|-------------------|
| subjects affected / exposed          | 0 / 383 (0.00%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)   |
| occurrences (all)                    | 0                  | 0                 | 0                 |
| Post herpetic neuralgia              |                    |                   |                   |
| subjects affected / exposed          | 0 / 383 (0.00%)    | 0 / 192 (0.00%)   | 1 / 381 (0.26%)   |
| occurrences (all)                    | 0                  | 0                 | 1                 |
| Migraine                             |                    |                   |                   |
| subjects affected / exposed          | 0 / 383 (0.00%)    | 0 / 192 (0.00%)   | 1 / 381 (0.26%)   |
| occurrences (all)                    | 0                  | 0                 | 1                 |
| Headache                             |                    |                   |                   |
| subjects affected / exposed          | 137 / 383 (35.77%) | 34 / 192 (17.71%) | 81 / 381 (21.26%) |
| occurrences (all)                    | 139                | 35                | 81                |
| Dizziness                            |                    |                   |                   |
| subjects affected / exposed          | 1 / 383 (0.26%)    | 1 / 192 (0.52%)   | 0 / 381 (0.00%)   |
| occurrences (all)                    | 2                  | 1                 | 0                 |
| Carpal tunnel syndrome               |                    |                   |                   |
| subjects affected / exposed          | 1 / 383 (0.26%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)   |
| occurrences (all)                    | 1                  | 0                 | 0                 |
| Blood and lymphatic system disorders |                    |                   |                   |
| Lymphadenitis                        |                    |                   |                   |
| subjects affected / exposed          | 1 / 383 (0.26%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)   |
| occurrences (all)                    | 1                  | 0                 | 0                 |
| Lymphadenopathy                      |                    |                   |                   |
| subjects affected / exposed          | 3 / 383 (0.78%)    | 1 / 192 (0.52%)   | 0 / 381 (0.00%)   |
| occurrences (all)                    | 3                  | 1                 | 0                 |
| Eye disorders                        |                    |                   |                   |
| Cataract                             |                    |                   |                   |
| subjects affected / exposed          | 0 / 383 (0.00%)    | 0 / 192 (0.00%)   | 1 / 381 (0.26%)   |
| occurrences (all)                    | 0                  | 0                 | 1                 |
| Vitreous floaters                    |                    |                   |                   |
| subjects affected / exposed          | 0 / 383 (0.00%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)   |
| occurrences (all)                    | 0                  | 0                 | 0                 |
| Vision blurred                       |                    |                   |                   |
| subjects affected / exposed          | 1 / 383 (0.26%)    | 0 / 192 (0.00%)   | 0 / 381 (0.00%)   |
| occurrences (all)                    | 1                  | 0                 | 0                 |
| Ocular retrobulbar haemorrhage       |                    |                   |                   |

|                             |                 |                 |                 |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)           | 0               | 0               | 1               |
| Diabetic retinopathy        |                 |                 |                 |
| subjects affected / exposed | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)           | 0               | 0               | 0               |
| Gastrointestinal disorders  |                 |                 |                 |
| Abdominal pain upper        |                 |                 |                 |
| subjects affected / exposed | 1 / 383 (0.26%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences (all)           | 1               | 1               | 0               |
| Abdominal pain              |                 |                 |                 |
| subjects affected / exposed | 2 / 383 (0.52%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)           | 2               | 0               | 1               |
| Abdominal wall haematoma    |                 |                 |                 |
| subjects affected / exposed | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)           | 0               | 0               | 0               |
| Haemorrhoids                |                 |                 |                 |
| subjects affected / exposed | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)           | 0               | 0               | 1               |
| Dyspepsia                   |                 |                 |                 |
| subjects affected / exposed | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)           | 0               | 0               | 1               |
| Dry mouth                   |                 |                 |                 |
| subjects affected / exposed | 1 / 383 (0.26%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)           | 1               | 0               | 0               |
| Diarrhoea                   |                 |                 |                 |
| subjects affected / exposed | 3 / 383 (0.78%) | 1 / 192 (0.52%) | 3 / 381 (0.79%) |
| occurrences (all)           | 3               | 1               | 3               |
| Hiatus hernia               |                 |                 |                 |
| subjects affected / exposed | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)           | 0               | 0               | 0               |
| Inguinal hernia             |                 |                 |                 |
| subjects affected / exposed | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)           | 0               | 0               | 1               |
| Large intestine polyp       |                 |                 |                 |
| subjects affected / exposed | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)           | 0               | 0               | 1               |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| Nausea                                 |                 |                 |                 |
| subjects affected / exposed            | 3 / 383 (0.78%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                      | 3               | 0               | 0               |
| Vomiting                               |                 |                 |                 |
| subjects affected / exposed            | 1 / 383 (0.26%) | 0 / 192 (0.00%) | 2 / 381 (0.52%) |
| occurrences (all)                      | 1               | 0               | 2               |
| Toothache                              |                 |                 |                 |
| subjects affected / exposed            | 1 / 383 (0.26%) | 1 / 192 (0.52%) | 1 / 381 (0.26%) |
| occurrences (all)                      | 1               | 1               | 1               |
| Poor dental condition                  |                 |                 |                 |
| subjects affected / exposed            | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                      | 0               | 0               | 0               |
| Odynophagia                            |                 |                 |                 |
| subjects affected / exposed            | 1 / 383 (0.26%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                      | 1               | 0               | 0               |
| Noninfective sialoadenitis             |                 |                 |                 |
| subjects affected / exposed            | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)                      | 0               | 0               | 1               |
| Hepatobiliary disorders                |                 |                 |                 |
| Hepatic steatosis                      |                 |                 |                 |
| subjects affected / exposed            | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                      | 0               | 0               | 0               |
| Hepatic fibrosis                       |                 |                 |                 |
| subjects affected / exposed            | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                      | 0               | 0               | 0               |
| Skin and subcutaneous tissue disorders |                 |                 |                 |
| Dermatitis atopic                      |                 |                 |                 |
| subjects affected / exposed            | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                      | 0               | 0               | 0               |
| Dermatitis allergic                    |                 |                 |                 |
| subjects affected / exposed            | 1 / 383 (0.26%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                      | 1               | 0               | 0               |
| Dermatitis                             |                 |                 |                 |
| subjects affected / exposed            | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                      | 0               | 0               | 0               |
| Actinic keratosis                      |                 |                 |                 |

|  |                      |                      |                      |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)   | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Dry skin<br>subjects affected / exposed<br>occurrences (all)                               | 1 / 383 (0.26%)<br>1 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Eczema nummular<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 383 (0.00%)<br>0 | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Erythema<br>subjects affected / exposed<br>occurrences (all)                               | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Macule<br>subjects affected / exposed<br>occurrences (all)                                 | 1 / 383 (0.26%)<br>1 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Urticaria<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 383 (0.00%)<br>0 | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Skin lesion<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Rash<br>subjects affected / exposed<br>occurrences (all)                                   | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Psoriasis<br>subjects affected / exposed<br>occurrences (all)                              | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Renal and urinary disorders<br>Dysuria<br>subjects affected / exposed<br>occurrences (all) | 0 / 383 (0.00%)<br>0 | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Acute kidney injury<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Musculoskeletal and connective tissue disorders  |                      |                      |                      |



|                             |                    |                  |                   |
|-----------------------------|--------------------|------------------|-------------------|
| Arthralgia                  |                    |                  |                   |
| subjects affected / exposed | 101 / 383 (26.37%) | 12 / 192 (6.25%) | 50 / 381 (13.12%) |
| occurrences (all)           | 102                | 12               | 51                |
| Back pain                   |                    |                  |                   |
| subjects affected / exposed | 4 / 383 (1.04%)    | 1 / 192 (0.52%)  | 3 / 381 (0.79%)   |
| occurrences (all)           | 4                  | 1                | 3                 |
| Rotator cuff syndrome       |                    |                  |                   |
| subjects affected / exposed | 0 / 383 (0.00%)    | 0 / 192 (0.00%)  | 0 / 381 (0.00%)   |
| occurrences (all)           | 0                  | 0                | 0                 |
| Musculoskeletal chest pain  |                    |                  |                   |
| subjects affected / exposed | 1 / 383 (0.26%)    | 0 / 192 (0.00%)  | 0 / 381 (0.00%)   |
| occurrences (all)           | 1                  | 0                | 0                 |
| Muscle spasms               |                    |                  |                   |
| subjects affected / exposed | 2 / 383 (0.52%)    | 0 / 192 (0.00%)  | 0 / 381 (0.00%)   |
| occurrences (all)           | 2                  | 0                | 0                 |
| Muscle contracture          |                    |                  |                   |
| subjects affected / exposed | 0 / 383 (0.00%)    | 0 / 192 (0.00%)  | 0 / 381 (0.00%)   |
| occurrences (all)           | 0                  | 0                | 0                 |
| Joint swelling              |                    |                  |                   |
| subjects affected / exposed | 1 / 383 (0.26%)    | 0 / 192 (0.00%)  | 0 / 381 (0.00%)   |
| occurrences (all)           | 1                  | 0                | 0                 |
| Myalgia                     |                    |                  |                   |
| subjects affected / exposed | 148 / 383 (38.64%) | 12 / 192 (6.25%) | 82 / 381 (21.52%) |
| occurrences (all)           | 149                | 13               | 83                |
| Infections and infestations |                    |                  |                   |
| Conjunctivitis              |                    |                  |                   |
| subjects affected / exposed | 0 / 383 (0.00%)    | 0 / 192 (0.00%)  | 0 / 381 (0.00%)   |
| occurrences (all)           | 0                  | 0                | 0                 |
| Ear infection               |                    |                  |                   |
| subjects affected / exposed | 0 / 383 (0.00%)    | 0 / 192 (0.00%)  | 1 / 381 (0.26%)   |
| occurrences (all)           | 0                  | 0                | 1                 |
| Chronic sinusitis           |                    |                  |                   |
| subjects affected / exposed | 0 / 383 (0.00%)    | 0 / 192 (0.00%)  | 2 / 381 (0.52%)   |
| occurrences (all)           | 0                  | 0                | 2                 |
| COVID-19                    |                    |                  |                   |

|                                  |                 |                 |                 |
|----------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed      | 2 / 383 (0.52%) | 1 / 192 (0.52%) | 5 / 381 (1.31%) |
| occurrences (all)                | 2               | 1               | 5               |
| Bronchitis                       |                 |                 |                 |
| subjects affected / exposed      | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 2 / 381 (0.52%) |
| occurrences (all)                | 0               | 0               | 2               |
| Oral herpes                      |                 |                 |                 |
| subjects affected / exposed      | 1 / 383 (0.26%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                | 1               | 0               | 0               |
| Otitis media                     |                 |                 |                 |
| subjects affected / exposed      | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)                | 0               | 0               | 1               |
| Gastrointestinal viral infection |                 |                 |                 |
| subjects affected / exposed      | 0 / 383 (0.00%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences (all)                | 0               | 1               | 0               |
| Herpes simplex                   |                 |                 |                 |
| subjects affected / exposed      | 1 / 383 (0.26%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                | 2               | 0               | 0               |
| Pharyngitis                      |                 |                 |                 |
| subjects affected / exposed      | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                | 0               | 0               | 0               |
| Labyrinthitis                    |                 |                 |                 |
| subjects affected / exposed      | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)                | 0               | 0               | 1               |
| Laryngitis                       |                 |                 |                 |
| subjects affected / exposed      | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                | 0               | 0               | 0               |
| Nasopharyngitis                  |                 |                 |                 |
| subjects affected / exposed      | 4 / 383 (1.04%) | 3 / 192 (1.56%) | 5 / 381 (1.31%) |
| occurrences (all)                | 4               | 3               | 5               |
| Influenza                        |                 |                 |                 |
| subjects affected / exposed      | 1 / 383 (0.26%) | 0 / 192 (0.00%) | 2 / 381 (0.52%) |
| occurrences (all)                | 1               | 0               | 2               |
| Pharyngitis streptococcal        |                 |                 |                 |
| subjects affected / exposed      | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                | 0               | 0               | 0               |
| Respiratory tract infection      |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed             | 0 / 383 (0.00%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences (all)                       | 0               | 1               | 0               |
| Respiratory tract infection viral       |                 |                 |                 |
| subjects affected / exposed             | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)                       | 0               | 0               | 1               |
| Rhinitis                                |                 |                 |                 |
| subjects affected / exposed             | 0 / 383 (0.00%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences (all)                       | 0               | 1               | 0               |
| Sinusitis                               |                 |                 |                 |
| subjects affected / exposed             | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)                       | 0               | 0               | 1               |
| Suspected COVID-19                      |                 |                 |                 |
| subjects affected / exposed             | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)                       | 0               | 0               | 1               |
| Tooth infection                         |                 |                 |                 |
| subjects affected / exposed             | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                       | 0               | 0               | 0               |
| Upper respiratory tract infection       |                 |                 |                 |
| subjects affected / exposed             | 2 / 383 (0.52%) | 0 / 192 (0.00%) | 5 / 381 (1.31%) |
| occurrences (all)                       | 2               | 0               | 5               |
| Urinary tract infection                 |                 |                 |                 |
| subjects affected / exposed             | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 1 / 381 (0.26%) |
| occurrences (all)                       | 0               | 0               | 1               |
| Viral infection                         |                 |                 |                 |
| subjects affected / exposed             | 1 / 383 (0.26%) | 2 / 192 (1.04%) | 0 / 381 (0.00%) |
| occurrences (all)                       | 2               | 2               | 0               |
| Viral upper respiratory tract infection |                 |                 |                 |
| subjects affected / exposed             | 2 / 383 (0.52%) | 1 / 192 (0.52%) | 0 / 381 (0.00%) |
| occurrences (all)                       | 2               | 1               | 0               |
| Metabolism and nutrition disorders      |                 |                 |                 |
| Diabetes mellitus inadequate control    |                 |                 |                 |
| subjects affected / exposed             | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                       | 0               | 0               | 0               |
| Type 2 diabetes mellitus                |                 |                 |                 |
| subjects affected / exposed             | 0 / 383 (0.00%) | 0 / 192 (0.00%) | 0 / 381 (0.00%) |
| occurrences (all)                       | 0               | 0               | 0               |

|  |                      |                      |                      |
|--|----------------------|----------------------|----------------------|
| Impaired fasting glucose<br>subjects affected / exposed<br>occurrences (all) | 0 / 383 (0.00%)<br>0 | 1 / 192 (0.52%)<br>1 | 0 / 381 (0.00%)<br>0 |
| Vitamin B12 deficiency<br>subjects affected / exposed<br>occurrences (all)   | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Dyslipidaemia<br>subjects affected / exposed<br>occurrences (all)            | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Electrolyte imbalance<br>subjects affected / exposed<br>occurrences (all)    | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Gout<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all)           | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 0 / 381 (0.00%)<br>0 |
| Hyperphagia<br>subjects affected / exposed<br>occurrences (all)              | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |
| Hypokalaemia<br>subjects affected / exposed<br>occurrences (all)             | 0 / 383 (0.00%)<br>0 | 0 / 192 (0.00%)<br>0 | 1 / 381 (0.26%)<br>1 |

| <b>Non-serious adverse events</b>   | Adults AIR-Placebo<br>Group | Adults AIR-RSV<br>Group |  |
|---|-----------------------------|-------------------------|--|
| Total subjects affected by non-serious<br>adverse events<br>subjects affected / exposed   | 72 / 191 (37.70%)           | 317 / 386 (82.12%)      |  |
| Neoplasms benign, malignant and<br>unspecified (incl cysts and polyps)<br>Uterine leiomyoma<br>subjects affected / exposed<br>occurrences (all) | 0 / 191 (0.00%)<br>0        | 0 / 386 (0.00%)<br>0    |  |
| Breast cancer<br>subjects affected / exposed<br>occurrences (all)   | 0 / 191 (0.00%)<br>0        | 1 / 386 (0.26%)<br>1    |  |
| Vascular disorders  |                             |                         |  |

|  |                         |                           |  |
|--|-------------------------|---------------------------|--|
| Hypertension<br>subjects affected / exposed<br>occurrences (all)               | 0 / 191 (0.00%)<br>0    | 1 / 386 (0.26%)<br>1      |  |
| General disorders and administration site conditions                           |                         |                           |  |
| Administration site bruise<br>subjects affected / exposed<br>occurrences (all) | 0 / 191 (0.00%)<br>0    | 1 / 386 (0.26%)<br>1      |  |
| Administration site warmth<br>subjects affected / exposed<br>occurrences (all) | 0 / 191 (0.00%)<br>0    | 1 / 386 (0.26%)<br>1      |  |
| Injection site pruritus<br>subjects affected / exposed<br>occurrences (all)    | 0 / 191 (0.00%)<br>0    | 3 / 386 (0.78%)<br>3      |  |
| Injection site pain<br>subjects affected / exposed<br>occurrences (all)        | 26 / 191 (13.61%)<br>26 | 285 / 386 (73.83%)<br>285 |  |
| Injection site induration<br>subjects affected / exposed<br>occurrences (all)  | 0 / 191 (0.00%)<br>0    | 0 / 386 (0.00%)<br>0      |  |
| Injection site erythema<br>subjects affected / exposed<br>occurrences (all)    | 1 / 191 (0.52%)<br>1    | 55 / 386 (14.25%)<br>55   |  |
| Injection site bruising<br>subjects affected / exposed<br>occurrences (all)    | 0 / 191 (0.00%)<br>0    | 0 / 386 (0.00%)<br>0      |  |
| Influenza like illness<br>subjects affected / exposed<br>occurrences (all)     | 0 / 191 (0.00%)<br>0    | 0 / 386 (0.00%)<br>0      |  |
| Fatigue<br>subjects affected / exposed<br>occurrences (all)                    | 36 / 191 (18.85%)<br>36 | 135 / 386 (34.97%)<br>135 |  |
| Chills<br>subjects affected / exposed<br>occurrences (all)                     | 0 / 191 (0.00%)<br>0    | 1 / 386 (0.26%)<br>1      |  |
| Chest pain   |                         |                           |  |

|   |                 |                   |  |
|---|-----------------|-------------------|--|
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%)   |  |
| occurrences (all)                               | 0               | 0                 |  |
| Asthenia  |                 |                   |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 1 / 386 (0.26%)   |  |
| occurrences (all)                               | 0               | 1                 |  |
| Injection site swelling                         |                 |                   |  |
| subjects affected / exposed                     | 1 / 191 (0.52%) | 43 / 386 (11.14%) |  |
| occurrences (all)                               | 1               | 43                |  |
| Peripheral swelling                             |                 |                   |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%)   |  |
| occurrences (all)                               | 0               | 0                 |  |
| Pyrexia   |                 |                   |  |
| subjects affected / exposed                     | 3 / 191 (1.57%) | 11 / 386 (2.85%)  |  |
| occurrences (all)                               | 3               | 11                |  |
| Reproductive system and breast disorders        |                 |                   |  |
| Dysmenorrhoea                                   |                 |                   |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%)   |  |
| occurrences (all)                               | 0               | 0                 |  |
| Respiratory, thoracic and mediastinal disorders |                 |                   |  |
| Asthma  |                 |                   |  |
| subjects affected / exposed                     | 1 / 191 (0.52%) | 2 / 386 (0.52%)   |  |
| occurrences (all)                               | 1               | 2                 |  |
| Dyspnoea  |                 |                   |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%)   |  |
| occurrences (all)                               | 0               | 0                 |  |
| Bronchospasm                                    |                 |                   |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%)   |  |
| occurrences (all)                               | 0               | 0                 |  |
| Chronic obstructive pulmonary disease           |                 |                   |  |
| subjects affected / exposed                     | 0 / 191 (0.00%) | 0 / 386 (0.00%)   |  |
| occurrences (all)                               | 0               | 0                 |  |
| Cough   |                 |                   |  |
| subjects affected / exposed                     | 1 / 191 (0.52%) | 0 / 386 (0.00%)   |  |
| occurrences (all)                               | 1               | 0                 |  |
| Sinus congestion                                |                 |                   |  |

|  |                 |                 |  |
|--|-----------------|-----------------|--|
| subjects affected / exposed                    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                              | 0               | 0               |  |
| Rhinorrhoea                                    |                 |                 |  |
| subjects affected / exposed                    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                              | 0               | 0               |  |
| Oropharyngeal pain                             |                 |                 |  |
| subjects affected / exposed                    | 2 / 191 (1.05%) | 2 / 386 (0.52%) |  |
| occurrences (all)                              | 2               | 2               |  |
| Nasal congestion                               |                 |                 |  |
| subjects affected / exposed                    | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                              | 0               | 1               |  |
| Epistaxis                                      |                 |                 |  |
| subjects affected / exposed                    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                              | 0               | 0               |  |
| Throat irritation                              |                 |                 |  |
| subjects affected / exposed                    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                              | 0               | 0               |  |
| Psychiatric disorders                          |                 |                 |  |
| Anxiety  |                 |                 |  |
| subjects affected / exposed                    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                              | 0               | 0               |  |
| Insomnia                                       |                 |                 |  |
| subjects affected / exposed                    | 1 / 191 (0.52%) | 1 / 386 (0.26%) |  |
| occurrences (all)                              | 1               | 1               |  |
| Investigations                                 |                 |                 |  |
| Blood pressure increased                       |                 |                 |  |
| subjects affected / exposed                    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                              | 0               | 0               |  |
| Helicobacter test positive                     |                 |                 |  |
| subjects affected / exposed                    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                              | 0               | 0               |  |
| Injury, poisoning and procedural complications |                 |                 |  |
| Contusion                                      |                 |                 |  |
| subjects affected / exposed                    | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                              | 0               | 1               |  |
| Immunisation reaction                          |                 |                 |  |

|                              |                 |                 |  |
|------------------------------|-----------------|-----------------|--|
| subjects affected / exposed  | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 0               | 0               |  |
| Meniscus injury              |                 |                 |  |
| subjects affected / exposed  | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 0               | 0               |  |
| Post-traumatic pain          |                 |                 |  |
| subjects affected / exposed  | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 0               | 0               |  |
| Soft tissue injury           |                 |                 |  |
| subjects affected / exposed  | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 0               | 0               |  |
| Rib fracture                 |                 |                 |  |
| subjects affected / exposed  | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 0               | 0               |  |
| Cardiac disorders            |                 |                 |  |
| Angina pectoris              |                 |                 |  |
| subjects affected / exposed  | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)            | 0               | 1               |  |
| Atrial fibrillation          |                 |                 |  |
| subjects affected / exposed  | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 0               | 0               |  |
| Supraventricular tachycardia |                 |                 |  |
| subjects affected / exposed  | 1 / 191 (0.52%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 1               | 0               |  |
| Palpitations                 |                 |                 |  |
| subjects affected / exposed  | 0 / 191 (0.00%) | 2 / 386 (0.52%) |  |
| occurrences (all)            | 0               | 2               |  |
| Cardiac failure chronic      |                 |                 |  |
| subjects affected / exposed  | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 0               | 0               |  |
| Cardiac failure              |                 |                 |  |
| subjects affected / exposed  | 1 / 191 (0.52%) | 0 / 386 (0.00%) |  |
| occurrences (all)            | 1               | 0               |  |
| Nervous system disorders     |                 |                 |  |
| Carotid arteriosclerosis     |                 |                 |  |



|                                      |                   |                    |  |
|--------------------------------------|-------------------|--------------------|--|
| subjects affected / exposed          | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 0                 | 0                  |  |
| Taste disorder                       |                   |                    |  |
| subjects affected / exposed          | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 0                 | 0                  |  |
| Sinus headache                       |                   |                    |  |
| subjects affected / exposed          | 1 / 191 (0.52%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 1                 | 0                  |  |
| Sciatica                             |                   |                    |  |
| subjects affected / exposed          | 1 / 191 (0.52%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 1                 | 0                  |  |
| Post herpetic neuralgia              |                   |                    |  |
| subjects affected / exposed          | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 0                 | 0                  |  |
| Migraine                             |                   |                    |  |
| subjects affected / exposed          | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 0                 | 0                  |  |
| Headache                             |                   |                    |  |
| subjects affected / exposed          | 32 / 191 (16.75%) | 106 / 386 (27.46%) |  |
| occurrences (all)                    | 33                | 106                |  |
| Dizziness                            |                   |                    |  |
| subjects affected / exposed          | 0 / 191 (0.00%)   | 1 / 386 (0.26%)    |  |
| occurrences (all)                    | 0                 | 1                  |  |
| Carpal tunnel syndrome               |                   |                    |  |
| subjects affected / exposed          | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 0                 | 0                  |  |
| Blood and lymphatic system disorders |                   |                    |  |
| Lymphadenitis                        |                   |                    |  |
| subjects affected / exposed          | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 0                 | 0                  |  |
| Lymphadenopathy                      |                   |                    |  |
| subjects affected / exposed          | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                    | 0                 | 0                  |  |
| Eye disorders                        |                   |                    |  |
| Cataract                             |                   |                    |  |

|                                |                 |                 |  |
|--------------------------------|-----------------|-----------------|--|
| subjects affected / exposed    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)              | 0               | 0               |  |
| Vitreous floaters              |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)              | 0               | 1               |  |
| Vision blurred                 |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)              | 0               | 0               |  |
| Ocular retrobulbar haemorrhage |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)              | 0               | 0               |  |
| Diabetic retinopathy           |                 |                 |  |
| subjects affected / exposed    | 1 / 191 (0.52%) | 0 / 386 (0.00%) |  |
| occurrences (all)              | 1               | 0               |  |
| Gastrointestinal disorders     |                 |                 |  |
| Abdominal pain upper           |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)              | 0               | 0               |  |
| Abdominal pain                 |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)              | 0               | 0               |  |
| Abdominal wall haematoma       |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)              | 0               | 1               |  |
| Haemorrhoids                   |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)              | 0               | 0               |  |
| Dyspepsia                      |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)              | 0               | 0               |  |
| Dry mouth                      |                 |                 |  |
| subjects affected / exposed    | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)              | 0               | 1               |  |
| Diarrhoea                      |                 |                 |  |
| subjects affected / exposed    | 2 / 191 (1.05%) | 4 / 386 (1.04%) |  |
| occurrences (all)              | 2               | 4               |  |

|  |                 |                 |  |
|--|-----------------|-----------------|--|
| Hiatus hernia                          |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                      | 0               | 1               |  |
| Inguinal hernia                        |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                      | 0               | 0               |  |
| Large intestine polyp                  |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                      | 0               | 0               |  |
| Nausea                                 |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 3 / 386 (0.78%) |  |
| occurrences (all)                      | 0               | 3               |  |
| Vomiting                               |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 2 / 386 (0.52%) |  |
| occurrences (all)                      | 0               | 2               |  |
| Toothache                              |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                      | 0               | 1               |  |
| Poor dental condition                  |                 |                 |  |
| subjects affected / exposed            | 1 / 191 (0.52%) | 0 / 386 (0.00%) |  |
| occurrences (all)                      | 1               | 0               |  |
| Odynophagia                            |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                      | 0               | 0               |  |
| Noninfective sialoadenitis             |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                      | 0               | 0               |  |
| Hepatobiliary disorders                |                 |                 |  |
| Hepatic steatosis                      |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                      | 0               | 1               |  |
| Hepatic fibrosis                       |                 |                 |  |
| subjects affected / exposed            | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                      | 0               | 1               |  |
| Skin and subcutaneous tissue disorders |                 |                 |  |

|                             |                 |                 |
|-----------------------------|-----------------|-----------------|
| Dermatitis atopic           |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)           | 0               | 1               |
| Dermatitis allergic         |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)           | 0               | 0               |
| Dermatitis                  |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)           | 0               | 1               |
| Actinic keratosis           |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)           | 0               | 1               |
| Dry skin                    |                 |                 |
| subjects affected / exposed | 1 / 191 (0.52%) | 0 / 386 (0.00%) |
| occurrences (all)           | 1               | 0               |
| Eczema nummular             |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)           | 0               | 0               |
| Erythema                    |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)           | 0               | 0               |
| Macule                      |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)           | 0               | 0               |
| Urticaria                   |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)           | 0               | 1               |
| Skin lesion                 |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)           | 0               | 1               |
| Rash                        |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)           | 0               | 1               |
| Psoriasis                   |                 |                 |
| subjects affected / exposed | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)           | 0               | 0               |

|   |                   |                    |  |
|---|-------------------|--------------------|--|
| Renal and urinary disorders                     |                   |                    |  |
| Dysuria   |                   |                    |  |
| subjects affected / exposed                     | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                               | 0                 | 0                  |  |
| Acute kidney injury                             |                   |                    |  |
| subjects affected / exposed                     | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                               | 0                 | 0                  |  |
| Musculoskeletal and connective tissue disorders |                   |                    |  |
| Arthralgia                                      |                   |                    |  |
| subjects affected / exposed                     | 19 / 191 (9.95%)  | 80 / 386 (20.73%)  |  |
| occurrences (all)                               | 19                | 81                 |  |
| Back pain                                       |                   |                    |  |
| subjects affected / exposed                     | 0 / 191 (0.00%)   | 1 / 386 (0.26%)    |  |
| occurrences (all)                               | 0                 | 1                  |  |
| Rotator cuff syndrome                           |                   |                    |  |
| subjects affected / exposed                     | 1 / 191 (0.52%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                               | 1                 | 0                  |  |
| Musculoskeletal chest pain                      |                   |                    |  |
| subjects affected / exposed                     | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                               | 0                 | 0                  |  |
| Muscle spasms                                   |                   |                    |  |
| subjects affected / exposed                     | 0 / 191 (0.00%)   | 1 / 386 (0.26%)    |  |
| occurrences (all)                               | 0                 | 1                  |  |
| Muscle contracture                              |                   |                    |  |
| subjects affected / exposed                     | 0 / 191 (0.00%)   | 1 / 386 (0.26%)    |  |
| occurrences (all)                               | 0                 | 1                  |  |
| Joint swelling                                  |                   |                    |  |
| subjects affected / exposed                     | 0 / 191 (0.00%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                               | 0                 | 0                  |  |
| Myalgia   |                   |                    |  |
| subjects affected / exposed                     | 26 / 191 (13.61%) | 122 / 386 (31.61%) |  |
| occurrences (all)                               | 26                | 122                |  |
| Infections and infestations                     |                   |                    |  |
| Conjunctivitis                                  |                   |                    |  |
| subjects affected / exposed                     | 1 / 191 (0.52%)   | 0 / 386 (0.00%)    |  |
| occurrences (all)                               | 1                 | 0                  |  |

|                                  |                 |                 |
|----------------------------------|-----------------|-----------------|
| Ear infection                    |                 |                 |
| subjects affected / exposed      | 1 / 191 (0.52%) | 0 / 386 (0.00%) |
| occurrences (all)                | 1               | 0               |
| Chronic sinusitis                |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                | 0               | 0               |
| COVID-19                         |                 |                 |
| subjects affected / exposed      | 1 / 191 (0.52%) | 2 / 386 (0.52%) |
| occurrences (all)                | 1               | 2               |
| Bronchitis                       |                 |                 |
| subjects affected / exposed      | 1 / 191 (0.52%) | 1 / 386 (0.26%) |
| occurrences (all)                | 1               | 1               |
| Oral herpes                      |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)                | 0               | 1               |
| Otitis media                     |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                | 0               | 0               |
| Gastrointestinal viral infection |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                | 0               | 0               |
| Herpes simplex                   |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                | 0               | 0               |
| Pharyngitis                      |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)                | 0               | 1               |
| Labyrinthitis                    |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                | 0               | 0               |
| Laryngitis                       |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)                | 0               | 1               |
| Nasopharyngitis                  |                 |                 |
| subjects affected / exposed      | 0 / 191 (0.00%) | 6 / 386 (1.55%) |
| occurrences (all)                | 0               | 6               |

|   |                 |                 |
|---|-----------------|-----------------|
| Influenza                               |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 0               | 0               |
| Pharyngitis streptococcal               |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 1 / 386 (0.26%) |
| occurrences (all)                       | 0               | 1               |
| Respiratory tract infection             |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 0               | 0               |
| Respiratory tract infection viral       |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 0               | 0               |
| Rhinitis                                |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 0               | 0               |
| Sinusitis                               |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 3 / 386 (0.78%) |
| occurrences (all)                       | 0               | 3               |
| Suspected COVID-19                      |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 0               | 0               |
| Tooth infection                         |                 |                 |
| subjects affected / exposed             | 1 / 191 (0.52%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 1               | 0               |
| Upper respiratory tract infection       |                 |                 |
| subjects affected / exposed             | 2 / 191 (1.05%) | 3 / 386 (0.78%) |
| occurrences (all)                       | 2               | 3               |
| Urinary tract infection                 |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 0               | 0               |
| Viral infection                         |                 |                 |
| subjects affected / exposed             | 1 / 191 (0.52%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 1               | 0               |
| Viral upper respiratory tract infection |                 |                 |
| subjects affected / exposed             | 0 / 191 (0.00%) | 0 / 386 (0.00%) |
| occurrences (all)                       | 0               | 0               |

|                                      |                 |                 |  |
|--------------------------------------|-----------------|-----------------|--|
| Metabolism and nutrition disorders   |                 |                 |  |
| Diabetes mellitus inadequate control |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                    | 0               | 1               |  |
| Type 2 diabetes mellitus             |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 2 / 386 (0.52%) |  |
| occurrences (all)                    | 0               | 2               |  |
| Impaired fasting glucose             |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                    | 0               | 0               |  |
| Vitamin B12 deficiency               |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                    | 0               | 1               |  |
| Dyslipidaemia                        |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                    | 0               | 0               |  |
| Electrolyte imbalance                |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                    | 0               | 0               |  |
| Gout                                 |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                    | 0               | 1               |  |
| Hyperglycaemia                       |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 1 / 386 (0.26%) |  |
| occurrences (all)                    | 0               | 1               |  |
| Hyperphagia                          |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                    | 0               | 0               |  |
| Hypokalaemia                         |                 |                 |  |
| subjects affected / exposed          | 0 / 191 (0.00%) | 0 / 386 (0.00%) |  |
| occurrences (all)                    | 0               | 0               |  |



**More information**

**Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? Yes

| Date        | Amendment   |
|-------------|---|
| 25 May 2023 | The purpose of this amendment was to record events of atrial fibrillation (AF) as Adverse Events of Special Interest (AESIs). |

Notes:

---

**Interruptions (globally)**

Were there any global interruptions to the trial? No

**Limitations and caveats**

None reported